



Deccan
Healthcare
Limited

StayWoW

ANNUAL REPORT

2020-2021



**EMPOWERING
WELLBEING.
DELIVERING
NUTRIENTS.**

Inside

CORPORATE INFORMATION

COMPANY AT A GLANCE

COMPANY OVERVIEW

- [Message from the Managing Director](#)
- [Our Covid-19 Response: Empowering WellBeing. Delivering Nutrients.](#)
- [From Farm To Nutrient Pills](#)
- [New Product Offerings in 2020-21](#)
- [Agile Superiority To Win With Consumers](#)
- [Awards & Recognition](#)
- [Our Nutrition Philosophy](#)
- [Financial Statements & Statutory Reports](#)





CORPORATE INFORMATION

KEY MANAGERIAL PERSONNEL

Mohak Gupta, CFO
Sheena Jain, Company Secretary &
Compliance Officer

LISTED ON STOCK EXCHANGE

Bombay Stock Exchange Limited (BSE)

REGISTERED OFFICE

#247, 2nd floor, Dwarakapuri Colony,
Punjagutta Hyderabad, Telangana-
500082

REGISTRAR & SHARE TRANSFER AGENTS

Bigshare Services Pvt. Ltd
306, Right Wing, 3rd Floor, Amrutha
Ville, Opp.Yashoda Hospital,
Somajiguda, Rajbhavan Road,
Hyderabad - 500082

STATUTORY AUDITOR

Keyur Shah & Co.,
Chartered Accountants

Board of Directors & Board of Advisors

BOARD OF DIRECTORS

**MINTO PURSHOTAM GUPTA,
MANAGING DIRECTOR**

MEENAKSHI GUPTA, DIRECTOR

**HITESH MOHANLAL PATEL,
DIRECTOR**

**SAMHITHA KANDLAKUNTA,
DIRECTOR**

RUCHI KHATTAR, DIRECTOR

SAVITA BHUTANI, DIRECTOR

BOARD OF ADVISORS

ARUN PANDEY

SATYAM BANSAL

NAREN KUMAR

KOUNDINYA KOSOORI





Who we are

We take care of Nutrition.
So, Nutrients can take care of you.
Traditional pills weren't doing it for us,
so we set out to reinvent Nutrient Pills
to fill in the gaps in our diet.



What we do

With science behind us and advanced research at our fingertips, we create powerful combinations of whole food vitamins and minerals to help you achieve your Wellness Goals.



How we do it

Nutrients feeds us physically, mentally, and emotionally. Nothing can be as powerful as plant superfoods and natural elixirs. And we are firm on sourcing the best, thoughtfully harvested ingredients.

Why we do it

To be one of the world's most innovative, trusted, science-led nutraceutical companies. We believe clean and the right nutrients goes a long way to maintain our well-being.



Message from the Managing Director



“

Despite the challenges, your Company remained resilient and focused on our strategic priorities. Our endeavour was to improve the quality of life by helping people Stay W.O.W, feel better and improve wellbeing.

COMPANY OVERVIEW

2020 was an extraordinary and challenging year for all of us. Financial Year 2020-21 will go down as one of the most challenging years for Deccan Health Care in our 25-year history. Despite the challenges, your Company remained resilient and focussed on our strategic priorities.

Empowering Wellbeing. Delivering Nutrients, best summarises your Company's response to the COVID-19 pandemic that brought economic activity around the world and India to a near-standstill. By being closely associated with our core purpose - Preventive Self Care, our biggest contribution has been to accelerate and enhance Wellbeing, while delivering nutrients to consumers.

Through our nutrient pills and meals, we improved the health of people in India. During the year under review, we delivered 100,000+ packs of nutrient pills and meals. This was even more exceptional considering the current challenging times we were all going through and were concerned about the safety and wellbeing of our families and loved ones. Given these circumstances, the

financial results delivered have been nothing less than noteworthy. Notwithstanding the challenges posed by disrupted supply chains and production lines due to the pandemic, your company adopted tireless efforts to keep the operations up and running. Our manufacturing facilities and workplaces attempted their best to ensure that our manufacturing and distribution network operated at optimum capacity.

At the same time, your Company's proactive action in adopting digital transformation and extending its reach has helped to keep-pace in resolving challenges and helped us drive engagement with stakeholders. The Company had revenue of Rs. 3383.12 Lakhs and EBDITA of Rs. 51.91 Lakhs, EPS of 0.25, with a market capitalisation of Rs. 4619.74 Lakhs in FY 2020-21

Equally, innovation of preventive self-care impact is at the heart of what we do in India, exemplified by the recent launch of immunity-boosting pills and drops. Before we go into more detail on our financial year results, I want to briefly outline the immediate

priorities we established to carry us through the pandemic:

- Protect the health and well-being of DHCL people;
- Maximise the availability of our products that help people and their families with their health, hygiene and nutrient needs, which have never been greater;
- Support the communities, relief agencies and people on the front lines of this global pandemic.

On behalf of the Board of Directors, I would like to say how proud I am of our teams, particularly our field force, manufacturing and distribution teams, who went above and beyond their call of duty to keep our people safe and also deliver business.

We wish to provide a commitment to all our stakeholders that DHCL will continue to deliver on our responsibilities and sail through short-term challenges.

We believe your company is well placed to deliver on its long-term strategic ambitions and its core purpose.

M P Gupta

Our Covid-19 response: Empowering Wellbeing. Delivering Nutrients.

Since the outbreak of the COVID-19 pandemic, DHCL has stayed true to its purpose of helping people improve their quality of life, feel better and stay W.O.W, and provided continued access to essential preventive self-care products.



INCREASED INPUT COST OF RAW MATERIALS, PACKAGING MATERIALS:

- Building new channel partnerships to make proactive healthcare products - nutrient pills available to consumers and business partners



SUPPLY CHAIN DISRUPTION: CONTACTLESS DELIVERY

- Partnered with local transport providers having an online delivery platform, for contactless delivery of proactive healthcare products - nutrient pills to consumers



EMPLOYEE WELL-BEING AND WORKFORCE DISRUPTION:

- Implementation of new SOP to speed up the process of returning to normal operation and profitability for the business, during and post-pandemic through the installation of sanitising and disinfecting facilities. Application of Antimicrobial Coating Proper with use of E-Sprayer, proper use of our Power Mister, Temperature check and health vitals assessment.



RESTRICTED MOVEMENT OF MARKETING TEAM: REACH THROUGH SOCIAL MEDIA

- #beyondbharat', a nationwide social media campaign to empower the general public with self-care prevention strategies.



STOCK DISRUPTION:

- Government regulations have been restricting full production, the company is adjusting production lines and ramping up manufacturing of proactive healthcare products - nutrient pills and in-demand products.



LABOUR & MANPOWER DISRUPTION:

- As contractual workers returned to their villages, engaging high-cost trained persons, curtailing non-essential additional costs.



INFORMATION & DATA

DISRUPTION:

- Transforming manual operations at varied locations and hotspot zones in the country. Increased investment and expenses towards technology for digital transformation to avoid future disruptions.



INCREASED CARRIER

TRANSPORT COSTS:

- Divert resources to critical issues to ensure the orders for proactive healthcare products - nutrient pills and other products are fulfilled .



FINANCIAL IMPACT:

- Increase in expenses and costs of procurement and finishing goods. Curtailing non-essential costs. Ensure financial health of channel partners.



DEMAND SURGE:

- Servicing increased demand for immunity range and preventive care products. Strategising production capacity shortage for meeting popular high-demand and essential proactive healthcare - nutrient pills products.

We spent the year building a stronger foundation and our goals this year will allow us to fulfil our mission for the consumers we serve. Our focus on consumers is unwavering. We work with our teams and various stakeholders to improve prevention through our product portfolio. As a science-and-innovation led nutraceutical company, we strive towards improving the quality of life of consumers, thus delivering them with hope when they need it the most.

As we build upon our learning from the last year and adapt ourselves to the new normal, the boundaries of what is possible are expanding ever outwards.

Taken together, our priorities ensure DHCL is there for the employees, consumers and communities who have always been there for us, and they remain in place today.

Importantly, they work hand-in-hand with our strategic choices – a portfolio of daily use nutrient products; meaningful superiority across products, packages, communication, online execution and value; driving productivity in everything we do; constructive disruption across all areas of our business; and a more empowered, agile and accountable organization.

This strategy is unwavering, and it's delivering strong, balanced growth and value creation.



BEYOUNGSTORE
#1 Emerging
Online
Nutrition Store
source: www.beyoungstore.com/awards

For more product information and product labels, visit the order products section on: www.beyoungstore.com

DECCAN HEALTH CARE:

FROM FARMS TO NUTRIENT PILL

An overview of our rigorous "Farm To Nutrient Pill" process:



Farm To Nutrient Pill is our commitment to ensuring the highest quality, safety and effectiveness of all DHCL products. While the process is far more extensive, Farm To Nutrient Pill is founded on three main standards:

Ingredients with purpose

We are invested in new discoveries, responsible farming and advanced production methods to craft the best products possible. Our team consists of leading nutrition and health experts

Care at every stage

We go to great lengths to ensure DHCL products meet or exceed a variety of industry standards in quality. You can be confident in the purity and effectiveness of our individual ingredients, as well as the integrity of our processes.

Nutrients you can trust

Environment where our products are stored – ensuring they are just as pure and powerful when you receive them as when they were first developed.

DID YOU KNOW?

The DHCL Innovation & Manufacturing facility spans an incredible 43,560 sq. ft. and has a green fencing; making it the growing nutrition facility. Opened in 2010, it enhances our ability to deliver top nutrition products to people around the globe.



OUR FARMERS SEED
THE FIELDS



AND CULTIVATE
THE LAND



TO ENSURE
QUALITY



IS GUARANTEED
THROUGHOUT



UNTIL IT'S IN
YOUR HANDS



INGREDIENTS WITH PURPOSE

We are invested in responsible farming and advanced production methods to craft the best products possible. We have a team of scientists and manufacturers from around the Country dedicated to identifying only the best sources of ingredients.



MADE WITH CARE

We go to great lengths to ensure our products meet or exceed a variety of industry standards in quality. You can be confident in the purity and value of our individual ingredients, as well as the integrity of our processes.



NUTRITION DELIVERED TO YOU

Improvising on new technology, we carefully monitor the environment where our products are stored – ensuring they are just as beneficial and powerful when you receive them as when they were first developed.

Our staff, state-of-the-art equipment and quality control systems throughout the entire manufacturing process help us ensure every product meets Deccan Health Care's stringent standards of quality.



**Deccan
Healthcare
Limited**

StayWoW



NEW PRODUCT OFFERINGS IN 2020-21



13 NEW PRODUCTS LAUNCHED IN FY 2020-21
despite the pandemic-induced setbacks.
More in the pipeline for Indian &
International markets

GERMO FREE SANITIZER



- When we step out of home, our hands touch many common surfaces like elevator buttons, cab doors, train handles, or grocery carts that are a breeding ground of bacteria and viruses.
- Using an alcohol-based sanitizer when out of the home to prevent the spread of bacteria and viruses.
- When out of home, use GERMOFREE SANITIZER which has 70% alcohol content, and gives you instant germ protection without water.
- This antibacterial hand sanitizer gel has glycerine and aloe vera that leaves your skin feeling fresh and supple.
- This quick-drying, non-sticky formula also comes in a convenient size pack.

NEW PRODUCT OFFERINGS IN 2020-21



ZINCODECC TONIC & TABLET

- "Zincodecc is a unique combination of Multivitamins and Multimerals. This multi-mineral vitamin complex is used for the prophylaxis of health and improvement of the immunity. Whatever your growing young life throws at you, trust Zincodecc for immunity and to safeguard your diet & support your nutritional needs.
- Zinc maintains the body's defensive (immune) system to work. It plays a role in cellular function, wound healing, metabolism of carbohydrates and sensing taste and smell.
- With Vitamins B3, B6, B12, which contribute to normal energy release suitable for vegans and vegetarians, there's something for everyone.
- Vitamin D3, Zinc, Vitamin E contributes to the normal function of the immune system.
- Whether you're in the outdoors exploring, travelling, or playing, it's packed with the vitamins and minerals to complete your body's daily nutrient needs.



NEW PRODUCT OFFERINGS IN 2020-21



DECCAN 7 TULSI SATT DROPS TULSI HONEY

- "Tulsi popularly coined by Deccan Health Care as "God's own medicine" is revered as a sacred plant infused with healing powers.
- Deccan 7 Tulsi Satt Drops has strong anti-inflammatory properties, helps reduce inflammation, lower the risk of heart problems, rheumatoid arthritis and inflammatory bowel conditions.
- Tulsi is a rich source of antioxidants that can repair damage caused by free radicals and reduce stress caused by oxidants.
- This healthful and purifying blend of 7 special varieties of Tulsi balances your nervous system, offers clarity & calm to your mind and enhances overall physical & emotional well-being."




SONEHALDI HALDI & KESAR DROPS

- SONEHALDI a unique formulation made with saffron the most expensive herb on earth helps improve immunity and your overall health. Unlike other haldi drops, this Ayurvedic concoction is formulated with all the goodness of not just Curcumin but also Saffron.
- Saffron "GOD'S GOLD FOR HEALTH & FITNESS". This product contains immunomodulatory (Rasayana), anti-inflammatory (Shothahar), analgesic (Shulahar), and blood purifying (Rakta shodhaka) properties.
- It helps treat skin disorders (Tvagroga), cough, cold and allergic rhinitis (Kasa, Pratishyaya and Pinasa). Regular use helps improve overall health and well-being.



NEW PRODUCT OFFERINGS IN 2020-21



BRIDAL LOOK UBTAN BODY WASH



■ 'Bridal Look Ubtan body wash' is a no-mess easy to use body wash is prepared with a myriad of fresh, sun-dried and hand-pounded ingredients for deeply cleansing and illuminating the skin.

■ The natural ingredients of 'Bridal Look Ubtan body wash' helps rebuild flabby and drooping tissues, improve blood circulation & skin texture, provide anti-aging, anti-wrinkle, anti-rash, anti-blemishing, anti-bacterial, anti-tanning effects to the skin and nourish it.

■ As a beauty aid, Curcumin - the alkaloidal content of one of the main ingredients Turmeric reduces pigmentation, maintains skin's PH balance and makes the skin glow. Chickpea Flour open the blocked pores, maintain the secretions from glands and bleach the sun freckles. Saffron add to the lustre of the skin and make it glow. Almond Oil helps to protect, nourish & beautify of the skin. Omega 3 oil gives you the baby soft skin and Rose water improves your complexion and reduces skin redness.

HAWAIIAN AQUA BODY WASH



■ Hawaiian aqua body wash has a fresh-aquatic fragrance that reminds you of cool ocean breeze and gently rushing waves.

■ This body wash generates loads and loads of foam to make your bathing experience evoke memories of a seaside holiday.

■ Premium natural ingredients such as Shea Butter and Vitamin E give your skin ample moisture and nourishment.

■ Your skin loves it !!! Softens skin, fades scars, improves moisture levels, fights free radicals. Keeps skin healthy and glowing.

■ Fresh-aquatic fragrance for a sensual spa-like feel to your bath.

NEW PRODUCT OFFERINGS IN 2020-21



ZnC CHEWABLE POWER OF ZINC+ VITAMIN C

- ZnC NUTRIENT PILLS formulated with Vitamin C and Zinc are essential nutrients that play an important role in nutrition and maintenance of immune health.
- They play a vital role in optimal functioning of the immune system.
- Inadequacy or deficiency of Vitamin C and Zinc leads to impaired immune system with altered resistance to infections and weakened collagenous structures with delayed wound healing.
- ZnC available in Super Orange Chewables form is made with premium technology which offers faster absorption and action.
- Gentler on stomach. This natural pure Vitamin C & Zinc works to keep your immune system in check.
- The presence of Zinc and Vitamin C together helps fight infections more effectively.



NEW PRODUCT OFFERINGS IN 2020-21



DECCZYME JEERA & MIXED FRUIT



- "KUCH BHI KAHO, 2 CHAMACH DECCZYME SE PACHAO" potent Digestive Enzyme Syrup
- DeccZyme Digestive Enzyme Syrup is used to alleviate indigestion, flatulence, hyperacidity, bloating, stomach cramps and various other types of digestion related problems.
- DeccZyme Digestive Enzyme Syrup also increases appetite of body and maintains the metabolic activities of body.
- DeccZyme contains digestive enzymes, which are natural substances needed by the body to help break down and digest food.

PainRelief



Powerful, Targeted Relief Ayurvedic Oil



active for
acute pain relief



DR. QUITPAIN AYURVEDIC OIL

- "Alleviate symptoms of muscle aches and pain fast with Dr Quit Pain Ayurvedic Oil.
- The deep-penetrating formula contains Capsaicin (chilly oil) which work to soothe discomfort you may be experiencing from common body aches.
- This Ayurvedic oil acts quickly to provide you with temporary relief from minor arthritis, backaches, and muscle or joint pain, so you can get back to doing the things you love.
- Dr Quit Pain Ayurvedic Oil comes in a convenient one-time use sachet making it easier than ever to get the relief you need.
- Keep your muscle ache and pain flares in control with Dr Quit Pain Ayurvedic Oil.

NEW PRODUCT OFFERINGS IN 2020-21



IMMUNITY BOOSTER



- Deccan's Immunity Booster an all-natural, immune system support herbal nutrient pills consisting of an exclusive blend of immune system boosting with 8 herbs like Cinnamon, Tulsi, Giloy, Ginger, Clove, Turmeric,.
- This unique formula rejuvenates and strengthens the immune system against daily exposure to toxins, allergens, bacteria, and environmental hazards, helping to heal the body from the inside out. The finest blend of science and nature working to strengthen your immune system.
- Ashwagandha and Piper cubeba root. Ashwagandha manages cortisol levels and keeps you away from fatigue. It also helps improve the body's defense and build cell immunity. Giloy is an Ayurvedic herb that helps boost immunity. It is rich in antioxidants that help fight free radicals and keeps your cells healthy.

Agile Superiority to Win with Consumers

In 2019, we raised the bar on all aspects of superiority, in all 10 of our categories. With this new standard in place, we assessed our portfolio to be superior across all dimensions. Today, more than 70% of our portfolio is judged as superior — and we're making continuous improvements to respond to consumer wellness goals, improving options for consumers.

Let's look at how this comes to life in Immunity Care, keeping your immunity game up all the time with our science-based Immunity Care range that covers a comprehensive range of supplements and essentials. Natural, plant-based nutrient pills, tonic & drops that help keep your health in check by maintaining a strong immune system.



DECCAN 7 TULSI SATT DROPS IN TULSI HONEY

The unique healthful and purifying blend of 7 special varieties of Tulsi balances your nervous system, offers clarity & calm to your mind and enhances overall physical & emotional well-being. 7 Tulsi Satt Care popularly coined by Deccan Health Care as “God’s own medicine” is revered as a sacred plant infused with healing powers.



DECCAN SONEHALDI DROPS [HALDI & KESAR]

Deccan Sonehaldi Haldi & Kesar Drops is an unique formulation made with saffron the most expensive herb on earth that helps improve immunity and your overall health. Unlike other haldi drops, this Ayurvedic concoction is formulated with all the goodness of not just Haldi but also Saffron. Deccan Sonehaldi Haldi & Kesar Drops popularly coined as “GOD’S GOLD FOR HEALTH & FITNESS”.



SUPERIOR PRODUCTS

Together, these five elements drive category growth, build a brand value and provide the basis to build sustainable competitive advantage.

Products so good, consumers recognize the difference. Superior products raise expectations for performance in the category.



IMPROVED PACKAGING

We aim at improving packaging that attracts consumers, conveys brand equity, helps consumers select the best product for their wellness goals, and delights consumers during use.



DECCAN HERBAL IMMUNITY BOOSTER

Deccan's Immunity Booster provides vital nutrients needed by the immune system to maintain optimal function. Exclusive blend of 8 natural herbs and ingredients such as Ginger, Clove, Turmeric, Ashwagandha and Piper cubeba root. Ashwagandha manages cortisol levels and keeps you away from fatigue. It also helps improve the body's defense and build cell immunity. Giloy is an Ayurvedic herb that helps boost immunity. It is rich in antioxidants that help fight free radicals and keeps your cells healthy.



CURCUMIN C3 COMPLX PLUS

Curcumin C3 Complex Plus™ Nutrient Pills Contains BioPerine (Black Pepper) to help increase the absorption of Curcumin. Curcumin, an active ingredient of Turmeric comes with a lot of medicinal properties which is essential to keep pathogens and germs in check. Curcumin has become very popular as an anti-aging and immunity boosting nutrient pill as advised by Ministry of Ayush, India.



ZINCODECC TONIC & TABLET

Zinc maintains the body's defensive (immune) system to work. It plays a role in cellular function, wound healing, metabolism of carbohydrates and sensing taste and smell. With Vitamins B3, B6, B12, which contribute to normal energy release suitable for vegans and vegetarians, there's something for everyone. Vitamin D3, Zinc, Vitamin E contributes to the normal function of the immune system. The goodness of Iodine helps control the body's metabolism and many other important functions for growth and development. Improves metabolism and physiological functions of the body.



SALES EXECUTION

BeyoungStore expanding reach efforts __ like the#beyoungbharat has helped grow new BeyoungStore users



CONSUMER & INFLUENCER VALUE EQUATION

At beyoungstore, a trained health and wellness influencer creates immersive wellness experiences like supporting physical health and mental wellbeing aspects, enhanced by nutrition education in-house IT and software supports a meaningful consumer connection, contributing to BeyoungStore's growing online share.



INFLUENCER COMMUNICATION

This combination of product, quality, nutrition communication and consumer delight that delivers consumer delight that support BeyoungStore's premium position

Recognitions and Awards

DHCL's dedication to growth allows us to serve the world's consumers better and create shareholder value in the process. These recognitions demonstrate our impact as a force for good and a force for acceleration.



COMPLIANCE



**C MISSION COMPLIANCE 10/10
TEAM COMPLIANCE AWARD 2020**



**DIVERSITY
& INCLUSION**



**15 Most Inspiring Women in Business
Exeleon Magazine USA**



**COMMUNITY
IMPACT**



**BS 10 Most Trustworthy
Companies to Watch**

Business Sight



**BRANDS &
INNOVATION**



**CIMS MEDICA
HEALTHCARE EXCELLENCE
AWARDS 2020**

**INNOVATIVE ONLINE WELLNESS STORE
BEYOND STORE**


OUR NUTRITION PHILOSOPHY

**Everybody is different.
Every body is Different.
So are their wellness goals.**

It's All About RDA

Our nutrition philosophy is simple: it's a combination of balanced nutrition, healthy activity and a personalised program with support from our Beyoung Bharat team

Let's break it down. So you know you need to eat right, but what does eating "right" really mean? For optimal well-being, make sure you're covered in the following areas:



DID YOU KNOW?

Just as your body needs proper nutrition for long-term health, your skin and hair require the right attention to look their best. Deccan Health Care offers Personal Care, Consumer Health Products to choose from.

BENEFIT NUTRI BLENDS



BENEFIT NUTRI BLENDS



DAILY NUTRIENT PILLS



IMMUNITY CARE



HEART CARE



PERSONAL CARE



ORAL CARE



CELEBRITY NUTRIENT Brightening Serum

Brighten your skin like never before with the CELEBRITY NUTRIENT Brightening Serum. This serum contains Almond and Vitamin E, moisturizes the skin deeply and its lightweight texture is perfect for any time, anywhere rejuvenation. Elevate your senses with its energising aroma as you apply it.



ZnC NUTRIENT PILLS

Vitamin C and Zinc are essential nutrients and play an important role in nutrition and maintenance of immune health. ZnC, available in Super Orange Chewables form is made with premium technology which offers faster absorption and action.



CardoDecc™ NUTRIENT Pills

CardoDecc™ Nutrient Pills is loaded with antioxidants Omega 3, 6, and 9 which helps maintain a healthy heart. CardoDecc™ Nutrient Pills has been scientifically developed to help safeguard your diet & support all round heart health and circulation. It provides a unique combination of Vitamins A, C, D3, E along with specific nutrients including CoenzymeQ10 and Lycopene.



Revolution Toothpaste Complete Natural Dental Care with Activated Charcoal

Naturally cleanses your teeth without any harsh whitening peroxides. With the power of Activated Charcoal, Laung (Clove) Ext., Omega-3 nature's best purifies and detoxifiers, this unique formula clears your teeth over time and helps remove stains from a number of causes like coffee-stains, wine, cigarettes, and more.



Celebrity NUTRIENT Hair Serum

It is the perfect choice for healthy maintenance of hair. Hair Serum has combined the natural properties of nutrients and organic essential extracts of shikakai and almond to create an absorbent hair treatment serum. This works to deliver the benefits for beautiful, healthy-looking hair: smoothness, volume, conditioning, strength, and Shine. Almond helps reduce hair loss.

DAILY HEALTH NUTRIENT CARE



PRODUCTS FOR USE BY ADULTS



SPECIALIZED NUTRITION | ADULT BOOSTER FERTILITY AND FEEL YOUR BEST



Protein+ Delicious Protein with Natural Coffee

It is a natural coffee based protein shake powder packed with 75 micronutrients, which help to fight diseases by stabilizing metabolic reactions, and provide adequate Protein for the day along with RDA (Recommended Daily Allowances) of our body.



OMG NUTRIENT Pills

OMG Nutrient Pills is the next generation breakthrough product developed to promote increased sexual stamina and arousal. The comprehensive tailored formulation for sexually active men & women, OMG Nutrient Pills is formulated with the ethnobotanical science of ingredients which are responsible for sexual arousal, promotes a healthy libido, sex drive and desire in partners.



My-75-Micronutrients™ NUTRIENT Pills

My-75-Micronutrients™ is the comprehensive formulation of 75 Micronutrients, Scientifically developed containing 14 Vitamins, 14 Minerals, 22 Amino Acids and 25 Natural extracts which are proven as powerful antioxidants, cell protectors, revitalizers, anti-inflammatory and anti-stress ingredients. Micronutrients have been shown to play a key role in preventing specific disease conditions.



Oxyflax® Global NUTRIENT Pills

Essential Fatty Acids are considered essential as they cannot be made by the body, Omega-3 fatty acids have to be consumed with the diet. With Alpha Linolenic acid, a rich source of Omega 3 fatty acids, Oxyflax® Global Nutrient Pills is a better way to source nutrients to our body naturally. ALA Omega 3 for Holistic Health and Wellness of Mind, Heart and whole Body.



Zorovit-M™ NUTRIENT Pills

27 vital nutrients for men of 20+ specially designed & developed for men of 20+ yrs of age to help maintain energy release, health and vitality in an otherwise hectic lifestyle. Zorovit-M Nutrient Pills provides a core source of the entire major vitamins and minerals; it also provides Zinc, Magnesium, Biotin, Brahmi, Ashwagandha Specifically for men's health.



THE BEYOUNGSTORE DIFFERENCE

BENEFIT NUTRI BLENDS

BEYOUNGSTORE is designed to support your wellness goals and help you turn them into reality. More than meal plans and regular activity, you need a support system to keep you on track and motivated. BEYOUNGSTORE provides a 360 degree, personalised solution to help you get the results you aspire to achieve



STEPPING UP AS A FORCE FOR GOOD IN RESPONSE TO COVID-19



Our people can work confidently knowing that DHCL stands behind them, with robust safety measures we constantly evaluate and update



We're bringing trusted brands that help Improve Quality of Life, take care of their personal health and hygiene, and create healthy homes for their families.



DHCL has a long history of supporting those in need, and we're supporting the communities, relief agencies and people on the front lines of this global pandemic.



PROTECTING OUR PEOPLE, WHILE WORKING FOR THEIR WELLBEING



HARNESSING DIGITAL CAPABILITIES




CARING FOR COMMUNITIES AMIDST COVID-19


- Our people can work confidently knowing that DHCL stands behind them, with robust safety measures we constantly evaluate and update
- We're bringing trusted brands that help people clean, take care of their personal health and hygiene, and create healthy homes for their families.
- DHCL has a long history of supporting those in need, and we're supporting the communities, relief agencies and people on the front lines of this global pandemic.

- Our investments in digital transformation since the last few years yielded fruitful results in business-continuity in a pandemic year.
- Maximizing the availability of products that help people and their families with their health, hygiene and nutrient needs, which have never been greater, by running shifts, putting equipment back into service quickly, partnering with suppliers, and constantly finding new ways to deliver more of the products consumers depend on.
- Leveraging our marketing expertise to support public health measures to help flatten the curve and slow the spread of the virus, through initiatives including hand-sanitising education from our BeYoung Hand Sanitizer brand.

- Using our R&D, nutrient and manufacturing expertise to make critically needed preventive care nutrient based immunity booster, hand sanitizer to support our operations and to share with housing societies, health care facilities and relief organizations.
- Creating a series of videos from DHCL and BeYoungStore and our other products to educate people on preventive care, the importance of nutrients in building the immune system and participating in events to bring needed attention and support to the most disproportionately affected populations.
- Helping ensure families have basic access to the everyday nutrients, health and wellbeing essentials many of us take for granted.



Strategising influencers to mass reach with one-to-one precision enabled by innovative products and technology



Building Community through focused nutrition education and training



Strategic in-house software and IT solutions - getting our hands on the keyboard for online sales



Creating brands for a purpose, to be a force for good, and a force for growth

(PIP) PRODUCT INFORMATION PERSONNEL MARKETING STRUCTURE

We designed social influencer selling to increase sales. Social influencer is taking part in community where consumers are encouraged to participate, listen understand, share and engage. 6000+ social influencers influence our sales. The SSI are trained in SSI skills by a professional Deccan Training Academy team.



DHCL's Integrated and Dynamically Predominate Strategies are Building the Foundation for Strong, Balanced Growth and Value Creation



Financial Statements & statutory Reports



MANAGEMENT DISCUSSION AND ANALYSIS REPORT

Indian Economy and Consumer sector overview

Indian Economy and Consumer sector overview Indian economy witnessed one of the toughest years in 2020. As per MOSPI (The Ministry of Statistics and Programme Implementation) release of First Advance Estimates, GDP for the financial year 2020-21 is likely to contract by 7.7%. In the context of recent history, the 7.7% contraction in GDP is a sharp one considering that India has registered an average annual GDP growth rate of 6.8% since the start of economic liberalization in 1992-93. After coping with the first wave of the pandemic, the economy showed some signs of recovery from quarter 3 of financial year 2020-21. Given the tremendous comeback during Q3 and Q4 financial year 2020-21 (with Q4 GDP growing by ~1.3%), the GDP forecast for financial year 2021-22 remains optimistic, ranging from 7.5% (by the UN) to as high as 11% (Goldman Sachs, Nomura, J P Morgan). The Indian FMCG industry had registered 7.3%* growth rate in quarter 3 of financial year 2020-21. The calendar year 2021 also started on a promising note with 9.4%* growth rate in quarter 4 of financial year 2020-21. As the country was looking forward for a sharp V shaped recovery in economy, the sudden resurgence of COVID-19 with second wave has hit the country hard, pushing many key Indian states into lockdown and city specific curfews and curbs. This brings major headwinds to the economic recovery of the country and the FMCG industry growth outlook which the country was looking forward in 2021. (*Source – Nielsen FMCG Quarterly Note Q1, 21).

The global nutraceuticals market is projected to grow at a CAGR of 7.5% during the forecast period (2020 - 2025). Globally, nutraceuticals are gaining importance and are becoming a part of the consumer's daily diet. The major reasons for this change have been the increasing prevalence of lifestyle diseases and people consciously taking preventive healthcare measures. Developed markets, like the United States and Europe, are discovering the untapped segment of customized products based on health claims.

Impact of COVID-19 on the Market:

The global nutraceuticals market is expected to witness consistent growth following the outbreak of COVID-19, as these include the food ingredients that provide medical or health benefits to prevent diseases as well as boosts the overall immune system. The flexibility in storage options, the demand for combined formulations with multiple benefits, increased consumer education levels, informed consumers, and the rise in health concerns among connected consumers are expected to fuel the demand for the market during the forecast period. ICMR has rolled out a large clinical study on Ayush ingredient for immunity, which has been tested on over 10,000 police personnel. Hence, the pandemic has highlighted the rightful use of nutraceutical as a preventive cure, and going forward, the global nutraceuticals industry is expected to get its rightful place in global healthcare and medical space, with a significant growth in the overall market.

The wave of COVID-19 in India has already started showing its effect on the economy and many ratings agencies have reduced the country's growth rate forecast, based on various macroeconomic factors. Some of key factors that may impact are:

❑ Weak consumer sentiment: One key factor that could negatively impact the demand outlook is weak consumer sentiment. It may be noted that the second COVID-19 wave has not only claimed thousands of lives but has also led to massive loss of livelihood due to rising unemployment rate. This is leading to a sharp drop in consumer sentiments.

❑ Rising inflationary pressure: There are mainly three inflationary concerns that could squeeze discretionary consumption, rising cost towards healthcare, higher fuel and inflation in essential commodity prices.

☒ Health and Wellness taking the lead: The changed consumer behavior towards hygiene and health during the COVID-19 crisis has also increased the demands for sanitizers and disinfectants, healthy food options like nutrient meals and immunity building alternatives and items.

☒ Other external factors: Global events leading to price fluctuations for crude oil; Milk quality and collection during the year; Agricultural output and good monsoons; One other aspect to be highlighted is the role of consumption, at-home digitization and e-commerce that has evolved tremendously over the last year. As a larger number of people are ordering online, digital has become one of the preferred channels for brand communication and social media has opened up another avenue to connect with consumers and will continue to do so going forward.

Year 2020-21 for the Company

The year 2020-21 has been very eventful and challenging with the pandemic induced setbacks impacting sales of key products. Despite COVID19 being in backdrop for the year 2020-21, the Company has managed to stay resilient and achieve a satisfactory performance during the year. The key vectors behind the Company's performance during the financial year are:

A. Continuous innovations across products: Continuous innovations across products: During 2020-21, amidst the ongoing pandemic crisis, the Company's Marketing and R&D teams worked relentlessly on innovation which were more relevant to the current times and which could fit into the consumer's need for healthier products. Some of the key new products which the Company launched in 2020-21 are as follows:

- ☒ Germo Free Hand Sanitizer
- ☒ ZincoDecc Tonic - Multivitamin, Mineral Strengthens the immune system and helps fight immune deficiency in a convenient syrup
- ☒ DeccZyme Mixed Fruit - Digestive syrup
- ☒ ZincoDecc Tabs- Multivitamin, Mineral tablet strengthens the immune system and helps fight immune deficiency
- ☒ Deccan 7 Tulsi Satt in Tulsi Honey - Launched to participate and penetrate in the Drops markets innovated 7 Rare Tulsi Drops
- ☒ ZnC Personal 14Pills Pack - on the go 14 pills weekly pack, Zinc & Vitamin C chewables in super orange
- ☒ ZnC Chewables- Zinc & Vitamin C chewables in super orange
- ☒ Deccan Herbal Immunity Booster Pills
- ☒ Deccans Sonehaldi Drops [Haldi & Kesar]- Launched to participate and penetrate in the Drops markets innovated Saffron and Curcumin drops
- ☒ DeccZyme Jeera - Digestive syrup with the goodness of Jeera
- ☒ DeccZyme Mixed Fruit - Digestive syrup
- ☒ Bridal Look Ubtan Body Wash
- ☒ Hawaiian Aqua Body Wash
- ☒ Dr Quit Pain Oil Sachet - Launched to participate and penetrate in the sachet markets

B. Strong Go to Market reaching the consumer directly - capacity and capability building: the Company embarked on Project BeYoungBharat aimed to take direct reach of the Company to health conscious wellness consumers which the Company successfully managed to achieve by end of the financial year. The company established Home Shoppes in high-demand locations to improve the delivery time by catering to the pin codes serviced by this Home Shoppee. The Company also plans to supplement it with digitization of front end SI and PIP with hand held devices and gettag its direct Home Shoppes under its coverage.

C. Growth for emerging channels and markets: E-commerce has emerged as the one bright spot for the Company as the channel grew substantially. There is no denying that as the consumers become more adaptive to shopping online across categories and products, E-commerce will play a significant role in driving the future growth of the Company. As the Company continues to expand its footprints in new markets, international business has seen a

growth opportunity. With the focus to further expand share of revenue from the international market, the Company has served its clients and consumers in Mauritius, Nepal and Africa.

Material development in Human resources: Company has remained very committed to the safety of all its employees and partners. The company has taken steps to improve processes for better talent acquisition, performance evaluation, merit recognition, and higher productivity. The Company's employee strength as on 31st March, 2021 was 83. The Company has also undertaken initiatives to build stronger employee engagement and talent retention. Core policies to enhance efficiencies have been implemented. Company has remained very committed to the safety of all its employees and partners. We focus on enhancing employee well-being and potential. The company provides an invigorating workplace environment, attractive career growth, fair performance management and compensation and operational transparency.

Opportunities

☒ The growth of consumer demand for nutraceutical products is increasing due to the increasing awareness of nutraceutical products. Lifestyle changes & unhealthy food habits has led to transformation of medical preferences. Tapping opportunities in the export market, natural and traditional approaches are being accepted worldwide. Expansion in terms of introduction of new product line. The global health care products industry is growing at a very rapid pace which allows the Company to pursue aggressive expansion plans.

Threats

☒ Restriction of movement of materials and man-power during lockdowns and government imposed covid guidelines. A Constant increase in costs in terms of raw material and packaging costs, lack of clarity and standardization making the regulatory climate uncertain.

Outlook: Given the unrelenting spread of the second wave of pandemic and the large-scale impact on the lives of the people, the near-term outlook for the Indian economy is uncertain impacting the growth prospects. There are many unknowns today and hence, the near term outlook is extremely uncertain. The immediate focus remains on safety of people, protecting supply lines, serving demand and optimizing cost and cash.

Despite the near-term ambiguity, the Company remains confident of the medium to long-term growth prospects considering the various categories of products your Company deals in. Although the current situation is much more uncertain than normal, the Company is confident about its ability to manage the immediate crisis and come out of it successfully

Risks and Concerns: The analysis presented in the Impact of covid-19 on market and Opportunities and Threats Section of this Report throws light on the important risks and concerns faced by your Company. The strategy of your Company to de-risk against these factors is also outlined in the said Sections

Internal Control Systems and their adequacy: The Company has established a well-defined process of risk management, wherein the identification, analysis and assessment of the various risks, measuring the probable impact of such risks, formulation of risk mitigation strategy and implementation of the same takes place in a structured manner. Though the various risks associated with the business cannot be eliminated completely, all efforts are made to minimize the impact of such risks on the operations of the Company. Necessary internal control systems are also put in place by the Company on various activities across the board to ensure that business operations are directed towards attaining the stated organizational objectives with optimum utilization of resources. Apart from these internal control procedures, a well-defined and established system of internal audit is in operation. The results of operations and financial conditions are affected by numerous factors including the following: Supply and availability of raw material/traded goods; Competition from existing and new entrants; Performance of our distribution channel; Brand image; Rate of interest policies; Economic and Demographic conditions; and Changes in laws and regulations that apply to Nutraceutical Industry in domestic and overseas market.

Discussion on Financial Performance with respect to the Operational Performance:

The Company continued to show good financial performance in the fiscal year 2020-21, company recorded net sales of 3,383.12 Lakhs during the financial year 2020-21 as compared to 4230.13 Lakhs in the previous financial year. The Net Profit during the financial year 2020-21 was at 39 Lakhs as compared to a net profit of 1,008.74 Lakhs in financial year 2019-20 translating to Basic Earnings Per Share at 0.25 for the financial year 2020-21 as compared to 6.42 in financial year 2019-20 due to negative impact of covid-19 pandemic on the business of the Company.

Significant changes (i.e. change of 25% or more as compared to the immediately previous financial years) in Key Financial Ratios, along with explanation are as under:

- i) **Debtor turnover ratio** was 2.05 in FY 2020-21 as compared to 2.12 in FY 2019-20 with a net change of (3.31)
- ii) **Inventory turnover ratio** was 0.44 in FY 2020-21 as compared to 20.48 in FY 2019-20 with a net change of (7.07)
- iii) **Interest coverage ratio** was 5.81 in FY 2020-21 as compared to 56.31 in FY 2019-20 with a net change of (89.68). Reason of significant change- The change is due lower sales realisation and consequently lower margins during the Financial Year vis a vis Previous Year.
- iv) **Current ratio** was 5.23 in FY 2020-21 as compared to 4.84 in FY 2019-20 with a net change of 7.93
- v) **Debt- Equity Ratio** was 0.07 in FY 2020-21 as compared to 0.22 in FY 2019-20 with a net change of (20.27)
- vi) **Operating Profit margin** was 1.69 in FY 2020-21 as compared to 33.66 in FY 2019-20 with a net change of (94.97). Reason of significant change- The change is due lower sales realisation and consequently lower margins during the Financial Year vis a vis Previous Year.
- vii) **Net Profit Margin** was 1.15 in FY 2020-21 as compared to 23.88 in FY 2019-20 with a net change of (95.17). Reason of significant change- The change is due lower sales realisation and consequently lower margins during the Financial Year vis a vis Previous Year.
- viii) **Return on Net worth** was 0.51 in FY 2020-21 as compared to 13.23 in FY 2019-20 with a net change of (96.15). Reason of significant change- The change is due lower sales realisation and consequently lower margins during the Financial Year vis a vis Previous Year.

DIRECTORS' REPORT

To
The Members of
Deccan Health Care Limited

Your Directors' are pleased to present Twenty Fifth Annual Report on the business and operations of the Company, along with the Standalone & Consolidated Audited Financial Statements of the Company for the Financial Year ended on March 31, 2021.

Financial Results:

The Financial Statements of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under section 133 of the Companies Act, 2013 ("the Act"), read with Rule 7 of the (Companies Accounts) Rules, 2014. The standalone and consolidated financial performance of the Company, for the Financial Year ended on March 31, 2021 are summarized below:

Financial Summary or Highlights/Performance

(Rs. in Lakhs except EPS)

Particulars	For the Year	For the Year
	ended 31 st March, 2021	ended 31 st March, 2020
Revenue from Operations	3,377.58	4,224.41
Other Income	5.54	5.72
Total Revenue	3,383.12	4,230.13
Expenses :		
Cost of Material Consumed	2,273.90	2,338.65
Changes in Inventories of Finished Goods and Work-in-Progress	(430.88)	(663.78)
Employee Benefit Expenses	291.76	433.38
Other Expenses	1,039.04	948.65
Finance Cost	10.79	18.32
Depreciation and Amortization Expenses	146.60	141.73
Total Expenses	3,331.21	3,216.95
Profit / (Loss) Before Tax	51.91	1,013.18
Tax Expenses :		
Provision for Income Tax	13.91	177.02
Less : MAT Credit Entitlement		(177.02)
Deferred Tax	(0.99)	4.44
Profit / (Loss) for the period	39.00	1,008.74
Earnings Per Share :		
Basic	0.25	6.42
Diluted	0.25	6.42

Results of operations:

The Company recorded net sales of 3,383.12 Lakhs during the financial year 2020-21 as compared to 4230.13 Lakhs in the previous financial year. The Net Profit during the financial year 2020-21 was at 39 Lakhs as compared to a net profit of 1,008.74 Lakhs in financial year 2019-20 translating to Basic Earnings Per Share at 0.25 for the financial year 2020-21 as compared to 6.42 in financial year 2019-20 due to negative impact of covid-19 pandemic on the business of the Company.

Impact of Covid-19

The world has been continuously witnessing an unprecedented crisis as a result of Covid-19. In today's trying times for the world in general and our nation in particular, our focus is on ensuring the safety of our employees and all other stakeholders while we continue to work both on wellness and prevention of the pandemic. Healthy lives and protecting livelihood both are of utmost importance to us.

In the Company we have created a group of senior management team to monitor the events happening in the external environment and take suitable preventive and corrective measures to ensure continued safety of employees. The team has prepared a business continuity plan, disaster management plan.. We are happy to mention that we have been doing whatever possible for the country in terms of fight against Covid-19. During this pandemic the Company has launched Germa Free hand sanitizer so that consumers can take protective

measures from spreading Covid-19, Company has also launched Deccan's Immunity Booster and ZnC with Zinc & Vitamin C to boost the immunity. Our manufacturing facility is operating at a reasonable capacity utilization and we are ensuring that our products are available to consumers without interruptions. We have strengthened our supply chain with a specific focus on helping parties in surviving the difficult times. We have taken several steps aimed at ensuring the safety, which include social distancing in the office premises, sanitization of our office premises; plant location, thermal screening for employees working at sites, providing sanitizers, masks, gloves etc. to employees. Apart from following all protocols and guidelines issued by global health organizations like WHO for Covid-19 we have come out with our own advisory for the safety of our employees.

Dividend

In view of the future expansion plans, Board of Directors have not recommended any dividend for the financial year ended 31st March, 2021.

Issue of Equity Shares and changes in Share Capital:

During the Financial Year 2020-21, there was no change in the Share Capital of the Company.

Change in the Nature of Business

There is no change in the nature of business during the financial year 2020-21.

Material Changes and Commitments

No material changes and commitments affecting the financial position of the Company have occurred between the end of the financial year of the Company to which the financial statements relate and the date of the report.

Management Discussion and Analysis [MDA]

Management Discussion and Analysis Report as required under the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 forms part of this Annual Report.

Directors and Key Managerial Personnel

The following is the Composition of the Board of Director's as on 31st March, 2021

Name of the Director	Category
Mr. Minto Purshotam Gupta	Managing Director (Promotor)
Ms. Meenakshi Gupta	Executive Director (Promotor)
Mr. Hitesh Patel	Non-executive Director (Promotor)
Ms. Ruchi Khattar	Independent Director
Ms. Kandlakunta Samhitha	Independent Director
Ms. Savita Bhutani*	Independent Director (women Director)

Ms. Savita Bhutani (DIN 07995252) resigned from the Directorship of the Company w.e.f. 28th July, 2021 due to her personal reasons.

Mr. Narendra Singh (DIN 03191356) has resigned from the directorship of the Company w.e.f. 30th September, 2020.

Mr. Hitesh Patel (DIN 02080625) shall retire by rotation at the ensuing Annual General Meeting and being eligible, offer himself for re-appointment. The Board hereby recommends his re-appointment for approval of shareholders in the ensuing Annual General Meeting.

Ms. Ruchi Khattar (DIN: 01966349) and Ms. Kandlakunta Samhitha (DIN: 08891727), was appointed as an Additional Director (Independent Category) by the Board of Directors of the Company, on the recommendation of the Nomination and Remuneration Committee at their meeting held on 24th September, 2020 upto the ensuing Annual General Meeting. Pursuant to Section 149 of the Act, read along with the Rules framed thereunder, the Board has recommended their appointment by the Members at the ensuing Annual general Meeting i.e. 25th Annual General Meeting (AGM) of the Company.

Mr. Minto Purshotam Gupta was reappointed as Managing Director of the Company for the period of 3 (three) years, w.e.f. 31st August, 2019 by the members of the Company at the 23rd Annual General Meeting (AGM) held on 30th September, 2019.

Key Managerial Personnel

1. Mr. Mohak Gupta*
2. Ms. Sheena Jain, Company Secretary

Note:

*Mr. Uttam Kumar Singh has resigned from the services of Chief Financial Officer of the Company w.e.f. 19th August, 2020 and Mr. Mohak Gupta was appointed on his place w.e.f. 01st March, 2021

Remuneration of Directors, Key Managerial Personnel & Particulars of Employees

The information required under Section 197 of the Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 forms an integral part of this Report is attached as **Annexure – I**.

The statement containing particulars of employees as required under section 197 of the Companies Act, 2013 read with Rule 5(2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, will be provided upon request. In terms of Section 136 of the Companies Act, 2013, the Report and accounts are being sent to the members and others entitled thereto.

Board Meeting

During the year under review, Five (5) Board Meetings were held, the dates being, 31st July, 2020, 05th September, 2020, 24th September, 2020, 04th January, 2021 and 01st March, 2021.

The intervening gap between the Meetings was within the period prescribed under the Companies Act, 2013.

Attendance at the Board Meetings held during the FY 2020-21

Name of Director	31.07.2020	05.09.2020	24.09.2020	04.01.2021	01.03.2021
Minto Purshotam Gupta	Yes	Yes	Yes	Yes	Yes
Meenakshi Gupta	Yes	Yes	Yes	Yes	Yes
Ruchi Khattar#	N.A.	N.A.	N.A.	Yes	Yes
Hitesh Patel	Yes	Yes	Yes	Yes	Yes
Narendra Singh*	No	No	No	N.A.	N.A.
Savita Bhutani	Yes	Yes	Yes	No	No
Ms. Kandlakunta Samhitha#	N.A.	N.A.	N.A.	Yes	Yes

Ms. Ruchi Khattar and Ms. Kandlakunta Samhitha was appointed as Additional Director (Independent Category) w.e.f. 24th September, 2020

*Mr. Narendra Singh has resigned from the Directorship of the Company w.e.f. 30th September, 2020

Attendance at the Last AGM of the Company held on 29th September, 2020:

Name of Director	Attendance at the last AGM held on 29 th September, 2020
Minto Purshotam Gupta	Yes
Meenakshi Gupta	Yes
Ruchi Khattar	Yes
Hitesh Patel	Yes
Narendra Singh	No
Savita Bhutani	No
Ms. Kandlakunta Samhitha	No

Declaration by Independent Directors

Ms. Ruchi Khattar, Ms. Kandlakunta Samhitha and Ms. Savita Bhutani (Resigned w.e.f. 28th July, 2021) are the Independent Directors on the Board of your Company. In the opinion of the Board and as confirmed by these Directors, they fulfil the conditions specified in Section 149(6) of the Act and the Rules made thereunder about their status as Independent Directors of the Company.

Performance Evaluation

In compliance with the Companies Act, 2013, and the Listing Regulations, the Board has carried out the annual performance evaluation of the Directors individually as well as evaluation of the working of the Board and the committees of the Board, by way of individual and collective feedback from the Directors.

The following were the Evaluation Criteria:

(a) For Independent Directors:

- Knowledge and Skills
- Professional conduct
- Duties, Role and functions

(b) For Executive Director:

- Performance as Team Leader/Member
- Evaluating Business Opportunity and analysis of Risk Reward Scenarios
- Key Set Goals and Achievements
- Professional Conduct and Integrity
- Sharing of Information with the Board

The Directors expressed their satisfaction with the evaluation process.

Board Committees

During the year under review, the Board of Directors of your Company had constituted and re-constituted various Committees and approved the terms of reference / role in compliance with the provisions of the Companies Act, 2013 and SEBI (LODR) Regulations, 2015 viz. Following are the Committees of Board and its Members as at the financial year end date i.e. 31-03-2021.

Committees	Name of Director	Designation
1. Audit Committee	Ruchi Khattar	Chairman
	Hitesh Patel	Member
	Savita Bhutani	Member
	Kandlakunta Samhitha	Member

During the Financial Year ended 31st March, 2021, the Audit Committee met four (4) times on 31st July, 2020, 24th September, 2020, 04th January, 2021 and 01st March, 2021 and the requisite quorum was present at the Meeting.

2. Stakeholder Relationship Committee

Ruchi Khattar	Chairman
Hitesh Patel	Member
Savita Bhutani	Member
Kandlakunta Samhitha	Member

During the Financial Year ended 31st March, 2021, the Stakeholder Relationship Committee met once (1) on 31st July, 2020, and the requisite quorum was present at the Meeting.

3. Nomination & Remuneration Committee

Kandlakunta Samhitha	Chairman
Ruchi Khattar	Member
Savita Bhutani	Member
Hitesh Patel	Member

During the Financial Year ended 31st March, 2021, the Nomination & Remuneration Committee met thrice (3) on 05th September, 2020, 24th September, 2020 and 01st March, 2021 and the requisite quorum was present at the Meeting.

4. Corporate Social Responsibility

Minto Purshotam Gupta	Chairman
Hitesh Patel	Member
Savita Bhutani	Member

During the Financial Year ended 31st March, 2021, the Corporate Social Responsibility Committee met once (1) on 01st March, 2021 and the requisite quorum was present at the Meeting.

Company Secretary act as the Secretary to all the above four constituted Committees.

All decisions pertaining to the constitution of Committees, appointment of members and fixing of terms of reference / role of the Committees are taken by the Board of Directors.

Subsidiary Companies

The Company does not have any joint ventures or associate companies during the year under the review.

However, on 12th May, 2020, Beyoungstore Private Limited, a wholly owned subsidiary of Deccan Health Care Limited was incorporated having Authorised Capital of Rs. 10,00,000 (Rs Ten Lakhs) divided into 100,000 shares of Rs. 10/- each and Paid up Capital of Rs. 100,000 (Rs. One Lakh) divided into 10,000 shares of Rs. 10/- each.

Beyoungstore Private Limited commenced its business on 08th October, 2020.

Pursuant to the provisions of Section 129(3) of the Companies Act, 2013, a statement containing the salient features of financial statements is annexed in the Form **AOC-1** to the consolidated financial statements and hence not repeated here for the sake of brevity.

Consolidated Financial Statements

The Consolidated Financial Statements have been prepared by the Company in accordance with applicable provisions of the Companies Act, 2013, Accounting Standards and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The audited consolidated financial statements together with Auditors' Report form part of the Annual Report. The Auditor's Report does not contain any qualification, reservation or adverse remark

Details about Related Party Transactions

No material Related Party Transactions i.e. transactions exceeding ten percent of the annual consolidated turnover as per the last audited financial statements were entered during the financial year of the Company. Accordingly, the disclosure of Related Party Transactions as required under Section 134(3)(h) of the Companies Act, 2013 in Form AOC-2 is not applicable

Details about Loans, Guarantee & Investment Under Section 186

During the year under review, the Company has complied with the provisions of the Section 186 of the Companies Act, 2013 and rules made thereunder.

Internal Control / Internal Financial Control Systems and Adequacy Thereof

Your Company has in place an adequate system of internal controls. The effectiveness of internal controls is reviewed through the internal audit process. Reports of internal auditors are reviewed by management and Audit Committee of the Company from time to time and desired actions are initiated to strengthen the control and effectiveness of the system.

Human Resources

The Company believes that quality of its employees is the key to success in long run. The Company continues to have cordial relations with its employees.

Conservation Of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo

The information with regard to Conservation of Energy, Technology Absorption, Foreign Exchange Earnings and Outgo in accordance with the provisions of Section 134(3)(m) of the Companies Act, 2013 read with Rule 8 of the Companies (Accounts) Rules, 2014, is given as **Annexure-II** forming part of this Report.

Auditors

a) Statutory Auditor

In the Annual General Meeting (AGM) of the Company held on 30th September, 2019, M/s. Keyur Shah & Co., Chartered Accountants, Ahmedabad, (FRN: 141173W), were appointed as the Statutory Auditors of the Company to hold office as the Statutory Auditors until the conclusion of the 28th Annual General Meeting (AGM) of the Company to be held in the year 2024.

Pursuant to the notification dated 7th May, 2018 issued by Ministry of Corporate Affairs, the requirement for ratification of appointment of Auditors by the shareholders at every Annual General Meeting has been done away with. Further, the Auditors have confirmed their eligibility under section 141 of the Companies Act, 2013 and the rules made thereunder.

Further, the report of the Statutory Auditors along with notes is enclosed to this report. The remarks in the Report are already explained in the Notes to Accounts and as such does not call for any further explanation or elucidation.

No fraud has been reported by the Statutory Auditors under Section 143(12) of the Companies Act, 2013 and the rules made thereunder.

B) Secretarial Audit

Pursuant to the provisions of Section 204 of the Companies Act, 2013 and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Company had appointed M/s. M. R. Bhatia & Co., a firm of Company Secretaries in Practice to undertake the Secretarial Audit of the Company for the Financial Year 2020-21. The Secretarial Audit Report is annexed herewith as **Annexure-III**.

The Secretarial Audit Report does not contain any qualification, reservation or adverse remark. No fraud has been reported by the Secretarial Auditors under Section 143 (12) of the Companies Act, 2013 and the rules made thereunder.

Corporate Social Responsibility (CSR)

During the year, the company has constituted the CSR Committee and framed CSR Policy. But the company has not spent any amount in CSR activities and is still identifying CSR Activities for amount to be spent. The Corporate Social Responsibility Report annexed to this Report as **Annexure –IV**.

Disclosure as per the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013:

The Company has zero tolerance towards sexual harassment at the workplace and has set up Internal Complaints Committee (ICC) for prevention, prohibition and redressal of sexual harassment at workplace in line with the provisions of the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013 and the Rules thereunder. During the year 2020-21, the Company has not received any complaint of sexual harassment.

Credit Rating

During the Financial Year, there was no credit rating being obtained by the Company.

Public Deposits

The Company has not accepted any deposits from the public/members under section 73 of the Companies Act, 2013, read with Companies (Acceptance of Deposits) Rule, 2014 during the year.

Directors' Responsibility Statement

To the best of their knowledge and belief and according to the information and explanations obtained by them, your Directors make the following statements in terms of Section 134 (5) of the Companies Act, 2013;

(a) That in the preparation of the annual accounts, the applicable accounting standards read with requirements set out under Schedule III to the Companies Act, 2013 have been followed along with proper explanation relating to material departures;

(b) That such accounting policies as mentioned in Notes to the Financial Statements have been selected and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true

and fair view of the state of affairs of the company as at March 31, 2019 and of the profit of the Company for the year ended on that date;

(c) That proper and sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of this Act for safeguarding the assets of the company and for preventing and detecting fraud and other irregularities;

(d) That the annual financial statements have been prepared on a going concern basis;

(e) That proper internal financial controls were in place and that the financial controls were adequate and were operating effectively;

(f) That systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.

Significant and Material Orders passed by the Regulators or Courts or Tribunals impacting the Going Concern Status of the Company

There has been no significant and material Order passed by the Regulators or Courts or Tribunals in the FY 2020-21, impacting the going concern status of the Company's operations.

Extract of Annual Return U/S 92 (3) in MGT-9

As per the provisions of Section 92(3) of the Companies Act, 2013 ('the Act') read with Rule 12(1) of the Companies (Management and Administration) Rules, 2014, the extract of the Annual Return in Form MGT-9 is given in **Annexure "V"**, forming part of this report.

Insider Trading

In compliance with the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015 (Regulations), your Company has adopted the following:

- i) Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders- The said Code lays down guidelines, which advise Insiders on the procedures to be followed and disclosures to be made in dealing with the shares of the Company and cautions them on consequences of non-compliances.
- ii) Code of Practices and Procedures of Fair Disclosures of Unpublished Price Sensitive Information- The Code ensures fair disclosure of events and occurrences that could impact price discovery in the market.
- iii) Policy for dealing with Unpublished Price Sensitive Information (UPSI) and Whistle Blower Policy for employees to report any leak or suspected leak of UPSI- The policy aims to enable the employees of the Company to report any leak or suspected leak of UPSI, procedures for inquiry in case of leak of UPSI or suspected leak of UPSI and initiate appropriate action and informing the SEBI promptly of such leaks, inquiries and results of such inquiries.
- iv) Internal Control Mechanism to prevent Insider Trading-The Internal Control Mechanism is adopted to ensure compliances with the requirements given in the regulations and to prevent Insider Trading. The Audit Committee reviewed and found the same in order.

Vigil Mechanism

The Company has adopted a Whistle Blower Policy establishing vigil mechanism, to provide a formal mechanism to the Directors and Employees to report their concerns about unethical behaviour, actual or suspected fraud or violation of the Company's Code of Conduct or ethics policy. The Policy provides for adequate safeguards against victimization of employees who avail of the mechanism.

Acknowledgements

Your Directors wish to place on record their appreciation of the contribution made by the employees at all level, towards the continued growth and prosperity of your company. Your Directors also wish to place on record their sincere thanks to the Banks and various Government Authorities for the support and co-operation extended to the Company. Your Directors are especially grateful to the shareholders for reposing their trust and confidence in the Company.

**By order of the Board of
Directors
For DECCAN HEALTH CARE LIMITED**

**Place: Hyderabad
Date: 06.09.2021**

**DR. MINTO P. GUPTA
Managing Director**

(DIN 00843784)

HITESH PATEL
Director
(DIN 02080625)

“Annexure - I”
DETAILS OF REMUNERATION OF DIRECTORS, KMPs AND EMPLOYEES
Pursuant to Section 197(12) of the Companies Act, 2013 read with Rule 5 of Companies
(Appointment & Remuneration) Rules, 2014

1.	The Ratio of the remuneration of each Director to the median remuneration of the employees of the Company for the Financial Year 2020-21	Director/KMP Name	Ratio of Remuneration of each Director/ to median Remuneration of employees
		Minto Purshottam Gupta	22.72
		Meenakshi Gupta	13.58

Note:

The aforesaid details are calculated on the basis of the gross remuneration received by the employees for the financial years 2019-20 & 2020-21.

2.	The Percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager if any in the Financial Year 2020-21	Director/KMP Name	% increase in remuneration
		Minto Purshotam Gupta	(21.85)
		Meenakshi Gupta	(32.44)
		Mohak Gupta**	2.62
		Sheena Jain	Nil
3.	The information of employees receiving salary in excess of the limits as prescribed under the provisions of Section 197 read with Rule 5, sub rule 2 & 3 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 and the Companies (Appointment and remuneration of Managerial Personnel) Amendment Rules, 2016 under the Companies Act, 2013, who were employed throughout or for a part of the financial year under review	Nil	
4.	Percentage increase in the median remuneration of employees in the Financial Year 2020-21	(47.85)	
5.	The Average percentile increase in salaries of employees other than managerial personnel in the last financial year and its comparison with the percentage increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration	(35.62)	
6.	Number of permanent employees on the rolls of the Company	47	
7.	Affirmation that the remuneration is as per the Remuneration Policy of the Company	It is hereby affirmed that the remuneration paid during the year is as per the Nomination and Remuneration Policy of the Company	

*Mr. Uttam Kumar Singh has resigned from the post of CFO w.e.f. 19th August, 2020

**Mr. Mohak Gupta was appointed as CFO of the Company w.e.f. 01st March, 2021

“ Annexure -II ”

Conservation of Energy, Technology Absorption and Foreign Exchange Earnings and Outgo

A. ENERGY CONSERVATION

Deccan Health Care Limited has always been a frontrunner in continually improving its operational performance in all areas, like productivity, yield, utilization and a host of other operating metrics, while reducing the consumption of fuel, power, stores and others. This is done by adopting an approach of continual improvement of process metrics across all energy consuming facilities.

The Company is continuously putting its efforts to improve Energy Management by way of monitoring energy related parameters on regular basis.

The Company is committed to transform energy conservation into a strategic business goal fully along with the technological sustainable development of Energy Management System. It is putting best endeavor to reduce energy consumption in its operations and activities.

To achieve above objectives the following steps are being undertaken by the Company: -

- Continuously monitoring the energy parameters such as maximum demand, power factor, load factor on regular basis;
- Continuously replacing the inefficient equipment's with latest energy efficient technology & upgradation of equipment's continually;
- Increasing the awareness of energy saving within the organization to avoid the wastage of energy;
- To enhance utilization of Renewable Energy Resources;
- Exploring the feasibility of utilization of Solar Power at plant locations wherever possible;

B. RESEARCH AND DEVELOPMENT (R&D)

Research, Technology and innovation continue to be one of the key focus areas to drive growth. In addition to developing new design, pattern and styles of Company's product, it also works on building new capabilities. To support this, Company avails services of qualified and experienced professionals / consultants.

C. TECHNOLOGY ABSORPTION

The Company develops in-house Technology and is not dependent on any outside Technology/Source.

D. FOREIGN EXCHANGE EARNINGS AND OUTGO

During the financial year under review, there was no foreign exchange earnings and outgo.

Any gains or losses arising on account of exchange difference either on settlement or on transactions is accounted for in the Statement of Profit & Loss.

Annexure -III
SECRETARIAL AUDIT REPORT
For the Financial Year ended March 31, 2021

[Pursuant to Section 204(1) of the Companies Act, 2013 and Rule No. 9 of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014]

To,
The Members,
Deccan Health Care Limited, Hyderabad
(L72200TG1996PLC024351)

We have conducted the Secretarial Audit of the compliance of applicable statutory provisions and the adherence to good corporate practices by Deccan Health Care Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided us a reasonable basis for evaluating the corporate conducts/statutory compliances and expressing my opinion thereon.

Based on our verification of the Company's books, papers, minute books, forms and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of secretarial audit, we hereby report that in our opinion, the Company has, during the audit period ended on March 31, 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board compliance-mechanism in place to the extent, in the manner and subject to the reporting made hereinafter:

We have examined the books, papers, minute books, forms and returns filed and other records maintained by the Company for the period ended on March 31, 2021 according to the provisions of:

- I. The Companies Act, 2013 ("the Act") and the Rules made thereunder;
- II. The Securities Contracts (Regulation) Act, 1956 ('SCRA') and the Rules made thereunder;
- III. The Depositories Act, 1996 and the Regulations and Bye-laws framed thereunder;
- IV. Foreign Exchange Management Act, 1999 and the Rules and Regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings; (Not Applicable to the Company during the Audit Period)
- V. The following Regulations and Guidelines prescribed under the Securities and Exchange Board of India Act, 1992 ('SEBI Act') to the extent applicable to the Company: -
 - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
 - b. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;

- c. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018;
- d. The Securities and Exchange Board of India (Share based Employee Benefits) Regulations, 2014;
- e. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008;
- f. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- g. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009 (Not Applicable to the Company during the Audit Period) ;
- h. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018 (Not Applicable to the Company during the Audit Period)
- i. The Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015;

VI. Other laws applicable specifically to the Company, namely:

- The Environment Protection Act, 1986;
- The Water (Prevention & Control of Pollution) Act, 1974;
- The Air (Prevention & Control of Pollution) Act, 1981;
- The Hazardous Waste (Management, Handling & Transboundary Movement) Rules, 2008;
- Factories Act, 1948;
- Industrial Disputes Act, 1947;
- The Payment of Wages Act, 1948;
- The Employee State Insurance Act, 1948;
- The Employee Provident Fund and Miscellaneous Provision Act, 1952;
- The Payment of Bonus Act, 1965;
- The Payment of Gratuity Act, 1972;
- The Income Tax Act, 1961 ;
- Contract Labor (Regulation and Abolition) Act, 1970;
- The Industrial Employment (Standing Orders) Act, 1946;
- The Goods and Service Tax Act, 2017;

We have also examined compliance with the applicable clauses of the following:

- i) Secretarial Standards (SS-1 and SS -2) issued by The Institute of Company Secretaries of India; and
- ii) The Listing Agreements entered into by the Company with the BSE Limited (SME Exchange) .

During the period under review the Company has complied with the provisions of the Act, Rules, Regulations, Guidelines, Standards, Listing Agreements etc mentioned above.

We further report that :

The Board of Directors of the Company is duly constituted with proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all directors to schedule the Board Meetings. Except where consent of the directors was received for scheduling meeting at a Shorter Notice, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarifications on the agenda items before the meeting and for meaningful participation at the meeting.

All decisions at Board Meetings and Committee Meetings were carried out unanimously as recorded in the minutes of the meetings of the Board of Directors or Committees of the Board, as the case may be.

The Company has obtained all necessary approvals under the various provisions of the Act; and there was no prosecution initiated and no fines or penalties were imposed during the year under review under the Act, SEBI Act, SCRA, Depositories Act, Listing Agreement and Rules, Regulations and Guidelines framed under these Acts against / on the Company, its Directors and Officers.

We further report that compliance of applicable financial laws including Direct and Indirect Tax laws by the Company has not been reviewed in the Audit since the same has been subject to review by the Statutory Auditors and other designated professionals .

We further report that there are adequate systems and processes in the company commensurate with the size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

For M. R. Bhatia & Co.
Practicing Company Secretaries

Monika R. Bhatia
Company Secretary
Proprietor
M. No. 10397
C.P. No.13348
UDIN: F010397C000879232

Place: Ahmedabad
Date: 02nd Sept 2021

Note: This report is to be read with our letter of even date which is annexed as " ANNEXURE A " and forms an integral part of this report.

"ANNEXURE A"

To,
The Members,
Deccan Health Care Limited, Hyderabad
(L72200TG1996PLC024351)

Our report of even date is to be read along with this letter.

1. Maintenance of Secretarial records is the responsibility of the management of the Company. Our responsibility is to express an opinion on these secretarial records based on our audit.
2. We have followed the audit practices and processes as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on the test basis to ensure that correct facts are reflected in Secretarial records. We believe that the processes and practices, we followed provide a reasonable basis for our opinion.
3. We have not verified the correctness and appropriateness of financial records and books of accounts of the Company.
4. We have obtained the Management representation about compliance of laws, rules and regulations and happenings of events etc.
5. The compliance of provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of the management. Our examination was limited to the verification of procedures on test basis.
6. The Secretarial Audit Report is neither an assurance as to the future viability of the Company nor of efficacy or effectiveness with which the management has conducted the affairs of the Company.
7. Due to COVID -19 outbreak and Lockdown situation, this Report has been issued relying on the certificate, information, details, data, documents and explanation provided by the Company and its officers, agents and authorized representatives and Registrar and Transfer Agent in electronic form, without physically verifying at their office.

For M. R. Bhatia & Co.
Practicing Company Secretaries

Monika R. Bhatia
Company Secretary
Proprietor
M. No. 10397
C.P. No.13348
UDIN: F010397C000879232

Place: Ahmedabad
Date: 02nd Sept 2021

"Annexure -IV "

REPORTING OF CORPORATE SOCIAL RESPONSIBILITY (CSR)

Pursuant to of Section 134(3)(o) of the Companies Act 2013, and Rule 9 of the Companies (Corporate Social Responsibility) Rules, 2014

1.	A brief outline of the Company's CSR Policy, including overview of projects or programmes proposed to be undertaken and a reference to the web link to the CSR Policy and projects or programmes.	<p>The Company has framed a Policy in compliance with the provisions of Companies Act, 2013.</p> <p>The Policy encompasses the Company's philosophy of "Serving Society through Industry" and is designed to employ Company's resources, strengths and strategies in discharging its responsibility as a Corporate Citizen.</p> <p>The Company continues to strive to transform the business environment in which it operates. It also works for the transformation of the Society. The aim of the Company is to create an environment which enhances opportunities for all the good things, better education, healthy lives and overall quality of living that life has to offer. The Company designs its CSR initiatives in alignment with its objective of enhancing the quality of life in all aspects.</p>
2.	Composition of the CSR Committee	<p>Dr. Minto P. Gupta - Chairman Mr. Hitesh Mohanbhai Patel - Member Ms. Savita Bhutani - Member</p>
3.	Average net profit of the Company for last three financial years	Rs. 840.59 Lakhs
4.	Prescribed CSR Expenditure (two percent of amount as in item 3 above)	16.81 Lakhs
5.	Details of CSR spent for the financial year: a) Total amount spent for the financial year b) Amount unspent, if any	<p>NIL</p> <p>Rs. 16.81 Lakhs</p>
6.	In case the Company has failed to spend the 2% of the average net profit of the last three financial years or any part thereof, reasons for not spending the amount	As the Company is yet to finalise its CSR projects, the Company did not incur any expenditure on any CSR activities during the financial year 20 20-21.
7.	Responsibility Statement	The Chairperson of the CSR Committee confirms that the implementation and monitoring of the CSR Policy, is in compliance with the CSR Objectives and Policy of the Company

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Place: Hyderabad
Date: 06.09.2020

DR. MINTO P. GUPTA
Managing Director (DIN 00843784)

"Annexure -V"
FORM NO. MGT -9
EXTRACT OF ANNUAL RETURN
as on the Financial Year ended on 31.03. 2021

[Pursuant to section 92(3) of the Companies Act, 2013 and
Rule 12(1) of the Companies (Management and Administration) Rules, 2014]

I. REGISTRATION AND OTHER DETAILS:	
i	CIN L72200TG1996PLC024351
ii	Registration Date 14 th June, 1996
iii	Name of the Company DECCAN HEALTH CARE LIMITED
iv	Category / Sub -Category of the Company Public Company – Limited by Shares
v	Address of the Registered office and contact details 247, 2 nd Floor, Dwarkapuri Colony, Punjagutta, Hyderabad, Telangana - 500082, India. E-mail: mailto@deccanhealthcare.co.in ; Contact: 040 -40144508; Website: www.deccanhealthcare.co.in
vi	Whether listed company Yes
vii	Name, Address and Contact details of Registrar and Transfer Agent, if any Big Share Services Private Limited 1st Floor, Bharat Tin Works Building, Opposite Vasant Oasis, Makwana Road, Marol, Andheri East, Mumbai - 400059 Tel No : +91 22 62638200; Fax No. : +91 22 62638299

II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY:

All the business activities contributing 10 % or more of the total turnover of the company shall be stated: -

Sl. No.	Name and Description of main products / services	NIC Code of the Product/ service	% to total turnover of the Company
1	Manufacture of Fast Moving Consumer Health Products (FMCHP)	21003	100%

III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES:

S. No.	Name and address of the company	CIN/GLN	Holding/ Subsidiary/Associate Company	% of shares held	Applicable section
1	-	-	-	-	-

a) Bodies Corporate	1950400	0	1950400	12.41	1404000	0	1404000	8.94	(3.47)
b) Individuals									
i) (Capital upto Rs. 1 Lakhs)	1026735	0	1026735	6.53	1560243	0	1560243	9.93	3.40
ii) (Capital Greater than Rs. 1 Lakhs)	4845416	0	4845416	30.83	6298989	0	6298989	40.09	9.26
c) Any Others (specify)									
i) Trusts	0	0	0	0	0	0	0	0	0
ii) Clearing Member	331070	0	331070	2.51	37384	0	37384	0.24	(2.27)
iii) Non Resident Indians	7800	0	7800	0.05	75600	0	75600	0.48	0.43
iv) Directors Relatives	0	0	0	0	0	0	0	0	0
v) Employee	0	0	0	0	0	0	0	0	0
vi) Overseas Bodies Corporates	0	0	0	0	0	0	0	0	0
vii) Unclaimed Suspense Account	0	0	0	0	0	0	0	0	0
viii) IEPF	0	0	0	0	0	0	0	0	0
ix) HUF	384995	0	384995	2.45	727000	0	727000	4.63	2.45
d) Qualified Foreign Investor	0	0	0	0	0	0	0	0	0
Sub -total (B)(2): -	8546416	0	8546416	54.39	10103216	0	10103216	64.30	9.91
Total Public Shareholding (B)=(B)(1)+(B)(2)	8546416	0	8546416	54.39	10103216	0	10103216	64.30	9.91
C. Shares held by Custodian for GDRs & ADRs	0	0	0	0	0	0	0	0	0
Grand Total (A+B+C)	15713430	0	15713430	100	15713430	0	15713430	100	0

ii) Shareholding of Promoters

Sl. No	Name	Shareholding at the beginning of the year (1.04.2020)			Share holding at the end of the year (31.03.2021)			% change in shareholding during the year
		No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	No. of Shares	% of total Shares of the Company	% of Shares Pledged / encumbered to total shares	
1	Vipul M Patel	142800	0.91	0.0000	19200	0.12	0.0000	-0.79
2	Bhavna Hitesh Patel	200000	1.27	0.0000	14000	0.09	0.0000	-1.18
3	Meenakshi Gupta	1707333	10.87	0.0000	1671333	10.64	0.0000	-0.23
5	Dr. Minto P . Gupta	2107667	13.41	0.0000	2107667	13.41	0.0000	0
6	Hitesh M ohanbhai Patel	3009214	19.15	0.0000	1798014	11.44	0.0000	-7.71
	TOTAL	7167014	45.61	0.0000	5610214	35.70	0.0000	-9.91

(iii) Change in Promoters' Shareholding (please specify, if there is no change):

Sl. No	Name	Shareholding		Increase/Decrease in Shareholding	Shareholding at the end of the year 31.03.2021	
		No. of Shares At the Beginning of the year 01.04.2019	% total Shares of the Company		No of Shares	% total Shares of the Company
1	Hitesh Mohanlal Patel	3009214	19.15	(1211200)	1798014	11.44
2	Dr. M into P. Gupta	2107667	13.41	0	2107667	13.41
3	Meenakshi Gupta	1707333	10.87	(36000)	1671333	10.64
4	Bhavna Hitesh Patel	200000	1.27	(186000)	14000	0.09
5	Vipul M Patel	142800	0.91	(123600)	19200	0.12
TOTAL		7167014	45.61	(1556800)	5610214	35.70

(iv) Shareholding Pattern of top ten Shareholders (other than Directors, Promoters and Holders of GDRs and ADRs):

Sr.No	Name	No. of Shares at the beginning/End of the year	Date	Increase/Decrease in share -holding	Reason	Number of Shares	Percentage of total shares of the company
1	KENT RO SYSTEMS LIMITED	9,68,800	31-Mar-20	0	Transfer	9,68,800	6.17
		9,68,800	31-Mar-21	0	Transfer	9,68,800	6.17
2	DIKSHA GREENS LIMITED	5,46,000	31-Mar-20	0	Transfer	5,46,000	3.47
			15-Jan-21	-6000	Transfer	5,40,000	3.44
			22-Jan-21	-50400	Transfer	4,89,600	3.12
			5-Feb-21	-16800	Transfer	4,72,800	3.01
			19-Feb-21	-87600	Transfer	3,85,200	2.45
			5-Mar-21	-20400	Transfer	3,64,800	2.32
			12-Mar-21	-31200	Transfer	3,33,600	2.12

			19-Mar-21		-26400	Transfer		3,07,200	1.96
			31-Mar-21	3,07,200	0	Transfer		3,07,200	1.96
3	VALUEWORTH CAPITAL MANAGEMENT PVT LTD		31-Mar-20	3,90,000	0	Transfer		3,90,000	2.48
			10-Apr-20		-19200	Transfer		3,70,800	2.36
			24-Apr-20		-16800	Transfer		3,54,000	2.25
			8-May-20		-1200	Transfer		3,52,800	2.25
			15-May-20		-4800	Transfer		3,48,000	2.21
			5-Jun-20		-200000	Transfer		1,48,000	0.94
			12-Jun-20		-12000	Transfer		1,36,000	0.87
			26-Jun-20		-135200	Transfer		800	0.01
			31-Mar-21	800	0	Transfer		800	0.01
4	NIHIR CHANDRAKANT SHAH		31-Mar-20	24,000	0	Transfer		24,000	0.15
			12-Jun-20		24000	Transfer		48,000	0.31
			18-Dec-20		51600	Transfer		99,600	0.63
			19-Feb-21		200400	Transfer		3,00,000	1.91
			5-Mar-21		50400	Transfer		3,50,400	2.23
			31-Mar-21	3,50,400	0	Transfer		3,50,400	2.23
5	HIRAL JAGDISH MALEKAR		31-Mar-20	0		Transfer		0	0.00
			12-Jun-20		268800	Transfer		2,68,800	1.71
			26-Feb-21		31200	Transfer		3,00,000	1.91
			31-Mar-21	3,00,000	0	Transfer		3,00,000	1.91
6	VISHAL BHANDARI .		31-Mar-20	1,75,000	0	Transfer		1,75,000	1.11
			5-Jun-20		100000	Transfer		2,75,000	1.75
			17-Jul-20		10800	Transfer		2,85,800	1.82
			24-Jul-20		-3600	Transfer		2,82,200	1.80
			31-Jul-20		-4800	Transfer		2,77,400	1.77

			14-Aug-20		-7200	Transfer	2,70,200	1.72
			9-Oct-20		-2400	Transfer	2,67,800	1.70
			13-Nov-20		-2400	Transfer	2,65,400	1.69
			11-Dec-20		-3600	Transfer	2,61,800	1.67
			18-Dec-20		-1200	Transfer	2,60,600	1.66
			5-Feb-21		6000	Transfer	2,66,600	1.70
			12-Feb-21		-16800	Transfer	2,49,800	1.59
			19-Feb-21		15600	Transfer	2,65,400	1.69
			26-Feb-21		4800	Transfer	2,70,200	1.72
			12-Mar-21		-8400	Transfer	2,61,800	1.67
			19-Mar-21		-13200	Transfer	2,48,600	1.58
			31-Mar-21		-2400	Transfer	2,46,200	1.57
		2,46,200	31-Mar-21		0	Transfer	2,46,200	1.57
7	PRASAD RAJNIKANT SHEETH	64,800	31-Mar-20		0	Transfer	64,800	0.41
			12-Jun-20		49200	Transfer	1,14,000	0.73
			31-Dec-20		-78000	Transfer	36,000	0.23
			19-Feb-21		200400	Transfer	2,36,400	1.50
		2,36,400	31-Mar-21		0	Transfer	2,36,400	1.50
8	SMITA ASHVIN SHAH	2,35,400	31-Mar-20		0	Transfer	2,35,400	1.50
			17-Apr-20		-7200	Transfer	2,28,200	1.45
			24-Apr-20		-1200	Transfer	2,27,000	1.44
			8-May-20		-3600	Transfer	2,23,400	1.42
			22-May-20		-2400	Transfer	2,21,000	1.41
			29-May-20		-1200	Transfer	2,19,800	1.40
			19-Jun-20		-2400	Transfer	2,17,400	1.38
			26-Jun-20		-22800	Transfer	1,94,600	1.24
			30-Jun-20		-4800	Transfer	1,89,800	1.21

			3-Jul-20		-2400	Transfer	1,87,400	1.19
			10-Jul-20		-1200	Transfer	1,86,200	1.19
			24-Jul-20		-6000	Transfer	1,80,200	1.15
			31-Jul-20		-16800	Transfer	1,63,400	1.04
			7-Aug-20		-6000	Transfer	1,57,400	1.00
			14-Aug-20		-25200	Transfer	1,32,200	0.84
			28-Aug-20		-6000	Transfer	1,26,200	0.80
			4-Sep-20		-6000	Transfer	1,20,200	0.77
			18-Sep-20		-7200	Transfer	1,13,000	0.72
			22-Sep-20		-1200	Transfer	1,11,800	0.71
			25-Sep-20		-2400	Transfer	1,09,400	0.70
			29-Sep-20		-2400	Transfer	1,07,000	0.68
			30-Sep-20		-4800	Transfer	1,02,200	0.65
			2-Oct-20		-3600	Transfer	98,600	0.63
			9-Oct-20		-13200	Transfer	85,400	0.54
			16-Oct-20		-7200	Transfer	78,200	0.50
			23-Oct-20		-9600	Transfer	68,600	0.44
			30-Oct-20		-9600	Transfer	59,000	0.38
			6-Nov-20		-15600	Transfer	43,400	0.28
			13-Nov-20		-18000	Transfer	25,400	0.16
			20-Nov-20		-2400	Transfer	23,000	0.15
			27-Nov-20		-22800	Transfer	200	0.00
		200	31-Mar-21		0	Transfer	200	0.00
9	PANTOMATH STOCK	2,31,600	31-Mar-20		0	Transfer	2,31,600	1.47
	BROKERS PRIVATE LIMITED							
			10-Apr-20		-1200	Transfer	2,30,400	1.47
			17-Apr-20		1200	Transfer	2,31,600	1.47

			24-Apr-20	-10800	Transfer	2,20,800	1.41
			8-May-20	-3600	Transfer	2,17,200	1.38
			15-May-20	-3600	Transfer	2,13,600	1.36
			22-May-20	2400	Transfer	2,16,000	1.37
			29-May-20	-1200	Transfer	2,14,800	1.37
			5-Jun-20	-1200	Transfer	2,13,600	1.36
			12-Jun-20	-6000	Transfer	2,07,600	1.32
			19-Jun-20	-22800	Transfer	1,84,800	1.18
			30-Jun-20	1200	Transfer	1,86,000	1.18
			3-Jul-20	-1200	Transfer	1,84,800	1.18
			31-Jul-20	-2400	Transfer	1,82,400	1.16
			7-Aug-20	-2400	Transfer	1,80,000	1.15
			14-Aug-20	-2400	Transfer	1,77,600	1.13
			21-Aug-20	-2400	Transfer	1,75,200	1.12
			28-Aug-20	-1200	Transfer	1,74,000	1.11
			4-Sep-20	-2400	Transfer	1,71,600	1.09
			18-Sep-20	-1200	Transfer	1,70,400	1.08
			22-Sep-20	-6000	Transfer	1,64,400	1.05
			9-Oct-20	2400	Transfer	1,66,800	1.06
			16-Oct-20	-2400	Transfer	1,64,400	1.05
			23-Oct-20	1200	Transfer	1,65,600	1.05
			30-Oct-20	1200	Transfer	1,66,800	1.06
			6-Nov-20	1200	Transfer	1,68,000	1.07
			11-Dec-20	-4800	Transfer	1,63,200	1.04
			25-Dec-20	1200	Transfer	1,64,400	1.05
			8-Jan-21	-9600	Transfer	1,54,800	0.99
			15-Jan-21	-144400	Transfer	10,400	0.07

			22-Jan-21		-7200	Transfer	3,200	0.02
			29-Jan-21		20800	Transfer	24,000	0.15
			5-Feb-21		-21600	Transfer	2,400	0.02
			12-Feb-21		-1200	Transfer	1,200	0.01
			19-Feb-21		-1200	Transfer	0	0.00
			19-Mar-21		1200	Transfer	1,200	0.01
			31-Mar-21	1,200	0	Transfer	1,200	0.01
10	NIKHIL GARG		31-Mar-20	1,99,600	0	Transfer	1,99,600	1.27
			31-Mar-21	1,99,600	0	Transfer	1,99,600	1.27
11	GITA KIRTI AMBANI		31-Mar-20	1,96,600	0	Transfer	1,96,600	1.25
			31-Mar-21	1,96,600	0	Transfer	1,96,600	1.25
12	SHAH SAURABH NARESHKUMAR HUF .		31-Mar-20	60,000	0	Transfer	60,000	0.38
			12-Jun-20		90000	Transfer	1,50,000	0.95
			22-Jan-21		27600	Transfer	1,77,600	1.13
			26-Feb-21		16800	Transfer	1,94,400	1.24
			31-Mar-21	1,94,400	0	Transfer	1,94,400	1.24
13	SANJAY JAISWAL		31-Mar-20	1,92,000	0	Transfer	1,92,000	1.22
			31-Mar-21	1,92,000	0	Transfer	1,92,000	1.22
14	SMITA VIRESH PATEL		31-Mar-20	1,64,400	0	Transfer	1,64,400	1.05
			31-Mar-21	1,64,400	0	Transfer	1,64,400	1.05

(v) Shareholding of Directors and Key Managerial Personnel:

Sl. No.	For each of the Directors and KMP	Shareholding at the beginning of the year 1-04-2020		Increase/ Decrease in shareholding, if any	Cumulative Shareholding during the year	
		No. of shares	% of total shares of the company		No. of shares	% of total Shares of the company
1	Dr. Minto P. Gupta and KMP)	2107667	13.41	-	2107667	13.41
2	Meenakshi Gupta (Director)	1707333	10.87	(36000)	1671333	10.64

3	Hitesh Mohanbhai Patel (Director)	3009214	19.15	(1211200)	1798014	11.44
4	Ruchi Khattar (Director)	0	0	-	0	0
5	Narendra Singh (Director)	0	0	-	0	0
6	Savita Bhutani (Director)	0	0	-	0	0
7	Kandlakunta Samhitha (Director)	0	0	-	0	0
8	Uttam Kumar Singh (KMP) *	0	0	-	0	0
9	Mohank Gupta (KMP) *					
10	Sheena Jain (KMP)	0	0	-	0	0

*Mr. Uttam Kumar Singh has resigned from the services of Chief Financial Officer of the Company w.e.f. 19th August, 2020 and Mr. Mohank Gupta was appointed on his place w.e.f. 01st March, 2021

V I. INDEBTEDNESS:

Indebtedness of the Company including interest outstanding/accrued but not due for payment: (Rs. in Lakhs)

	Secured Loans excluding deposits	Unsecured Loans	Deposits	Total Indebtedness
Indebtedness at the beginning of the financial year				
i) Principal Amount	106.69	22.75	0	129.44
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	106.69	22.75	0	129.44
Change in Indebtedness during the financial year				
• Addition	0	0	0	0
• Reduction	24.74	1.50	0	26.24

Net Change	(24.74)	(1.50)	0	(26.24)
Indebtedness at the end of the financial year				
i) Principal Amount	81.95	21.25	0	103.20
ii) Interest due but not paid	0	0	0	0
iii) Interest accrued but not due	0	0	0	0
Total (i+ii+iii)	81.94	21.25	0	103.20

VI I. REMUNERATION OF DIRECTORS AND KEY MANAGERIA

L P ERSONNEL:

A. Remuneration to Chairman, Managing Director & Whole

-time Directors:

(Amount in Lakhs .)

SN.	Particulars of Remuneration	Name of WTD/MD/Manager		
		Dr. Minto P. Gupta MD	Meenakshi Gupta WTD	
1	Gross salary (Rs. in Lakh)	51.59		30.61
	(a) Salary as per provisions contained in section 17(1) of the Income -tax Act, 1961	0		0
	(b) Value of perquisites u/s 17(2) Income -tax Act, 1961	0		0
	(c) Profits in lieu of salary under section 17(3) Income - tax Act, 1961	0		0
2	Stock Option	0		0
3	Sweat Equity	0		0
4	Commission - as % of profit - others, specify...	0		0
5	Others, please specify	0		0
	Total (A)	51.59		30.61
	Ceiling as per the Act (Rs. in Lakh)	Remuneration is being paid in accordance with Section 197 read with Schedule V of the Companies Act, 2013.		

B. REMUNERATION TO OTHER DIRECTORS

(Rs. in Lakh)

SN.	Particulars of Remuneration	Name of Director				
		Ruchi Khattar	Narendra Singh	Savita Bhutani	Hitesh M Patel	Kandlakunta Samhitha
1	Independent Directors					
	Fee for attending board/committee meetings	0	0	0	0	0
	Commission	0	0	0	0	0
	Others, please specify	0	0	0	0	0
	Professional Fees	0	0	0	0	0
	Total (1)	0	0	0	0	0
2	Other Non -Executive Directors					
	Fee for attending board/committee meetings	0	0	0	0	0
	Commission	0	0	0	0	0
	Others, please specify	0	0	0	0	0
	Total (2)	0	0	0	0	0
	Total (B)=(1+2)	0	0	0	0	0
	Overall Ceiling as per the Act (Rs. in Lakh)	Ceiling of Rs. 1,00,000/- (Rupees One lakh only) sitting fees per meeting as per the Companies Act, 2013 .				

C. REMUNERATION TO KEY MANAGERIAL PERSONNEL (OTHER THAN MD/MANAGER/WTD)

SN	Particulars of Remuneration	Mohak Gupta (Chief Financial Officer) *	Ms. Sheena Jain * (Company Secretary)
1	Gross salary (Rs. in Lakh)	17.97	7.13
	(a) Salary as per provisions contained in section 17(1) of the Income Act, 1961 -tax	0	0
	(b) Value of perquisites u/s 17(2) Income -tax Act, 1961	0	0
	(c) Profits in lieu of salary under section 17(3) Income -tax Act, 1961	0	0
2	Stock Option	0	0
3	Sweat Equity	0	0
4	Commission	0	0
	- as % of profit	0	0
	others, specify...	0	0
5	Others, please specify	0	0
	Total	17.97	7.13

* Mr. Mohak Gupta was appointed as Chief Financial Officer w.e.f. 01st March, 2021

V III. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:

Type	Section of the Companies Act	Brief Description	Details of Penalty / Punishment/ Compounding fees imposed	Authority [RD / NCLT/ COURT]	Appeal made, if any (give Details)
A. COMPANY					
Penalty			NIL		
Punishment					
Compounding					
B. DIRECTORS					
Penalty			NIL		
Punishment					
Compounding					
C. OTHER OFFICERS IN DEFAULT					
Penalty			NIL		
Punishment					
Compounding					

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Place: Hyderabad
Date: 06.09.2021

DR . MINTOP . GUPTA
Managing Director (DIN 00843784)

HITESH PATEL
Director (D IN 02080625)

INDEPENDENT AUDITOR'S REPORT

The Members of DECCAN HEALTH CARE LIMITED

Report on the Audit of the Standalone Financial Statements

Opinion

We have audited the Standalone Financial Statements of **DECCAN HEALTH CARE LIMITED** ("the Company"), which comprise the balance sheet as at 31st March 2021, and the statement of Profit and Loss, and Statement of Cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and profit/loss, and its cash flows for the year ended on that date.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Standalone Financial Statements* section of our report. We are independent of the Company in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Standalone Financial Statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon and we do not provide a separate opinion on these matters and there are no matter during the year to be reported as Key Audit Matters.

Information Other than the Standalone Financial Statements and Auditor's Report Thereon

The Company's board of directors is responsible for the preparation of the other information. The other information comprises the information included in the Board's Report including Annexure to Board's Report (but does not include the standalone financial statements and our auditor's report thereon) and the rest of the Annual Report (the "Other Information"). The Other information is expected to be made available to us after the date of this auditor's report.

Our opinion on the standalone financial statements does not cover the other information and we will not express any form of assurance conclusion thereon.

In connection with our audit of the standalone financial statements, our responsibility is to read the other information identified above when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the standalone financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

When we read the other information, if we conclude that there is a material misstatement therein, we are required to communicate the matter to those charged with governance.

Management's Responsibility for the Standalone Financial Statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these Standalone Financial Statements that give a true and fair view of the financial position, financial performance, of the Company in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Standalone Financial Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Standalone Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Statements

Our objectives are to obtain reasonable assurance about whether the Standalone Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Standalone Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Standalone Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and

obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Standalone Financial Statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the Standalone Financial Statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the '**Annexure A**' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid Standalone Financial Statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st march, 2021 taken on record by the Board of Directors, none of the directors is disqualified as on 31st march, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in “Annexure B”.
- (g) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
 - i. The Company has disclosed the impact of pending litigation which should require to disclose on its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W

Keyur Shah
Proprietor
M. No. 153774
UDIN: 21153774AAAAEK7233

Date: 13-07-2021
Place: Ahmedabad

“Annexure A” to the Independent Auditors’ Report

Referred to in paragraph 1 under the heading ‘Report on Other Legal & ‘Regulatory Requirement’ of our report of even date to the Standalone Financial Statements of the Company for the period ended March 31, 2021:

Fixed Assets:

- a) The Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets;
- b) The Fixed Assets have been physically verified by the management in a phased manner, designed to cover all the items over a period of three years, which in our opinion, is reasonable having regard to the size of the company and nature of its business. Pursuant to the program, however, there were certain fixed assets which were not verified during the year as planned due to outbreak of COVID–19 pandemic. As represented by the management, these will be covered for verification in the subsequent period. According to the information and explanations given to us, no material discrepancies were noticed on verification of the fixed assets.
- c) The Title deed of immovable properties are held in the name of the company.

Inventory:

- a) The management has conducted the physical verification of inventory at reasonable intervals.
- b) The discrepancies noticed on physical verification of the inventory as compared to books records which has been properly dealt with in the books of account were not material.

Loans given by the Company:

The company has not granted loans & advances to parties covered under section 189 of the Act

Loans to directors & Investment by the Company:

In our opinion and according to the information and explanations given to us, the company has complied with the provision of section 185 & 186 of the Companies Act, 2013 in respect of loans etc.

Deposits

The Company has not accepted any deposits from the public and hence the directives issued by the Reserve Bank of India and the provisions of Sections 73 to 76 or any other relevant provisions of the Act and the Companies (Acceptance of Deposit) Rules, 2015 with regard to the deposits accepted from the public are not applicable.

Cost Records

As informed to us, the maintenance of Cost Records has not been specified by the Central Government under sub-section (1) of Section 148 of the Act, in respect of the activities carried on by the company.

Statutory Dues:

- a) According to information and explanations given to us and on the basis of our examination of the books of account, and records, the Company has been generally regular in depositing

undisputed statutory dues including Provident Fund, Employees State Insurance, Income-Tax, Sales Tax, Goods and Services Tax, Service Tax, Duty of Customs, Duty of Excise, Value Added tax, Cess and any other statutory dues with the appropriate authorities except as mentioned below:

Name of the Statute	Nature of Dues	Amount (Rs. In Lakhs)	Period to which the amount relates	Due Date of Payment	Date of Payment
The Employees' State Insurance Act, 1948	Employer Contribution	0.15	April,2019	15th of May,2019	-
		0.05	May,2019	15th of June,2019	-
		0.04	June,2019	15th of July,2019	-
		0.02	July,2019	15th of Aug,2019	-
		0.02	Aug,2019	15th of Sep,2019	-
		0.02	Sep,2019	15th of Oct,2019	-
		0.02	Oct,2019	15th of Nov,2019	-
		0.01	Nov,2019	15th of Dec,2019	-
		0.01	Dec,2019	15th of Jan,2020	-
		0.01	Jan,2020	15th of Feb,2020	-
		0.02	Feb,2020	15th of April,2020	-
		0.02	March,2020	15th of May,2020	-
		0.02	April,2020	15th of May,2020	-
		0.02	May,2020	15th of June,2020	-
		0.02	June,2020	15th of July,2020	-
		0.04	July,2020	15th of Aug,2020	-
	0.04	Aug,2020	15th of Sep,2020	-	
	Employee Contribution	0.26	April,2019	15th of May,2019	-
		0.13	May,2019	15th of June,2019	-
		0.12	June,2019	15th of July,2019	-
		0.08	July,2019	15th of Aug,2019	-
		0.08	Aug,2019	15th of Sep,2019	-
		0.08	Sep,2019	15th of Oct,2019	-
		0.07	Oct,2019	15th of Nov,2019	-
		0.06	Nov,2019	15th of Dec,2019	-
		0.06	Dec,2019	15th of Jan,2020	-
0.06		Jan,2020	15th of Feb,2020	-	
Income Tax Act, 1961	Tax Deducted At Source and Tax Collected at Source	9.09	Aug'2019 to March' 2020	7 th of next month & for the March'2020 the date would be 30 th April,2020	9.09 paid in December, 2020
		30.92	Aug'2019 to	7 th of next month & for the March'2020	-

			March' 2020	the date would be 30 th April,2020		
		1.04	April' 2020 to Aug'2020	7 th of next month	-	
		2.87	April' 2020 to Aug' 2020	7 th of next month	2.87 Paid in July,2021	
EPF & MP Act, 1952	Employer Contribution	0.35	April,2019	15th of May,2019	0.12 paid on 21-08-2020	
		0.15	May,2019	15th of June,2019	0.11 paid on 27-08-2020	
		0.12	June,2019	15th of July,2019	0.10 paid on 28-08-2020	
		0.12	July,2019	15th of Aug,2019	0.09 paid on 06-10-2020	
		0.12	Aug,2019	15th of Sep,2019	0.09 paid on 08-10-2020	
		0.12	Sep,2019	15th of Oct,2019	0.08 paid on 29-10-2020	
		0.10	Oct,2019	15th of Nov,2019	-	
		0.09	Nov,2019	15th of Dec,2019	-	
		0.09	Dec,2019	15th of Jan,2020	-	
		0.09	Jan,2020	15th of Feb,2020	-	
		0.17	Feb,2020	15th of March,2020	-	
		0.16	March,2020	15th of May,2020	-	
		0.05	April,2020	15th of May,2020	-	
		0.04	May,2020	15th of June,2020	-	
	0.05	June,2020	15th of July,2020	Paid on 02-11-2020		
	0.05	July,2020	15th of Aug,2020	-		
	0.05	Aug,2020	15th of Sep,2020	-		
		Employee Contribution	0.60	April,2019	15th of May,2019	-
			0.14	May,2019	15th of June,2019	-
			0.11	June,2019	15th of July,2019	-
			0.11	July,2019	15th of Aug,2019	-
			0.11	Aug,2019	15th of Sep,2019	-
			0.11	Sep,2019	15th of Oct,2019	-
			0.09	Oct,2019	15th of Nov,2019	-
			0.09	Nov,2019	15th of Dec,2019	-
			0.08	Dec,2019	15th of Jan,2020	-
			0.08	Jan,2020	15th of Feb,2020	-
	0.16		Feb,2020	15th of March,2020	-	
	0.15		March,2020	15th of May,2020	-	
	0.04		April,2020	15th of May,2020	-	
	0.04	May,2020	15th of June,2020	-		
	0.04	June,2020	15th of July,2020	Paid on 02-11-2020		
	0.04	July,2020	15th of Aug,2020	-		

		0.04	Aug,2020	15th of Sep,2020	-
Income Tax Act, 1961	Income Tax	3.70	AY 2001-02		-
Income Tax Act, 1961	Income Tax	1.10	AY 2009-10		-
Income Tax Act, 1961	Income Tax	1.50	AY 2018-19		-

- b) According to the information and explanation given to us, there are no dues of income tax, sales tax, Goods & Service Tax, service tax, duty of customs, duty of excise, value added tax outstanding on account of any dispute except as mentioned below:

(Rs. in Lakhs)

Nature of Statute	Nature of Dues	Forum Where Dispute is pending	Period to Which the Amount Relates (Assessment Year)	Amount
Income Tax Act, 1961	Income Tax	Jurisdictional AO	2010-11	8.77 /-
Income Tax Act, 1961	Income Tax	CIT (A) 5-HYDERABAD	2017-18	451.12 /-
Income Tax Act, 1961	Income Tax	CIT (APPEAL)	2018-19	525.35/-
Income Tax Act, 1961	Income Tax	CIT (APPEAL)	2019-20	505.91/-

Repayment of Loans:

In our opinion and according to the information and explanations given to us, the Company has not defaulted in the repayment of dues to banks. The Company has not taken any loan from the government and has not issued any debentures. The Loans taken from financial institutions have been properly disclosed in Financial Statements & are repaid at regular intervals.

Utilization of IPO & FPO:

Based upon the audit procedures performed and the information and explanations given by the management, the company has not raised monies by way of initial public offer or further public offer including debt instruments.

Reporting of Fraud:

Based upon the audit procedures performed and the information and explanations given by the management, we report that no fraud by the Company or on the company by its officers or employees has been noticed or reported during the period.

Approval of Managerial Remuneration:

Based upon the audit procedures performed and the information and explanations given by the management, the managerial remuneration has been paid or provided in accordance with the requisite approvals mandated by the provisions of section 197 read with Schedule V to the Companies Act;

NIDHI Company:

In our opinion, the Company is not a Nidhi Company. Therefore, the provisions of clause 4 (xii)

of the Order are not applicable to the Company.

Related Party Transaction:

In our opinion, all transactions with the related parties are in compliance with section 177 and 188 of Companies Act, 2013 and the details have been disclosed in the Financial Statements as required by the applicable accounting standards.

Private Placement or Preferential Issues:

Based upon the audit procedures performed and the information and explanations given by the management, the company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review. Accordingly, the provisions of clause 3 (xiv) of the Order are not applicable to the Company and hence not commented upon.

Non Cash Transaction:

The company has not entered into non cash transaction with the directors or their relatives and hence provisions of section 192 of the Companies Act, 2013 are not applicable to the Company.

Register under RBI Act, 1934:

In our opinion, the company is not required to be registered under section 45 IA of the Reserve Bank of India Act, 1934 and accordingly, the provisions of clause 3 (xvi) of the Order are not applicable to the Company and hence not commented upon.

**For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W**

**Keyur Shah
Proprietor
M. No. 153774
UDIN: 21153774AAAAEK7233**

**Date: 13-07-2021
Place: Ahmedabad**

“Annexure B” to the Independent Auditor’s Report of even date on the Standalone Financial Statements of **DECCAN HEALTH CARE LIMITED**

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of **DECCAN HEALTH CARE LIMITED** (“the Company”) as of March 31, 2021 in conjunction with our audit of the Standalone Financial Statements of the Company for the period ended on that date.

Management’s Responsibility for Internal Financial Controls

The Board of Directors of the Company is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

Auditor’s Responsibility

Our responsibility is to express an opinion on the internal financial controls over financial reporting of the Company based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India and the Standards on Auditing prescribed under Section 143(10) of the Companies Act, 2013, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting of the Company.

Meaning of Internal Financial Controls over Financial Reporting with Reference to these Standalone Financial Statements

A company's internal financial control over financial reporting with reference to these Standalone Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting with reference to these Standalone Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements

Inherent Limitations of Internal Financial Controls over Financial Reporting With Reference to these Standalone Financial Statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to these Standalone Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Standalone Financial Statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these Standalone Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2021 based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

**For, Keyur Shah & Co.
Chartered Accountants
F.R.No. 141173W**

**Keyur Shah
Proprietor
M. No. 153774
UDIN: 21153774AAAAEK7233**

**Date: 13-07-2021
Place: Ahmedabad**



DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Statement of Assets and Liabilities as at 31st March, 2021

(Rs. in lakhs)

	Particulars	Note No.	As at 31st March, 2021	As at 31st March, 2020
I.	EQUITY AND LIABILITIES			
(1)	Shareholder's Funds			
	(a) Share Capital	2	1,571.34	1,571.34
	(b) Reserves and Surplus	3	6,090.87	6,051.86
(2)	Share Application Money pending allotment			
(3)	Non-Current Liabilities			
	(a) Long-Term Borrowings	4	66.63	86.85
	(b) Deferred Tax Liability	5	212.68	213.68
	(c) Long Term Provisions	6	14.08	15.38
(4)	Current Liabilities			
	(a) Trade Payables	7	565.64	705.97
	(b) Other Current Liabilities	8	505.45	463.44
	(c) Short-Term Provisions	9	200.07	190.47
	TOTAL		9,226.76	9,298.99
II.	ASSETS			
(1)	Non-Current Assets			
	(a) Property, Plant & Equipments			
	(i) Tangible Assets	10	1,987.41	2,124.83
	(ii) Intangible Assets		-	-
	(iii) Intangible Assets Under Development	10	6.66	-
	(b) Long-Term Loans and Advances	11	176.87	184.78
	(c) Other Non-Current Assets	12	410.08	403.40
	(d) Non-Current Investment	13	1.00	-
(2)	Current Assets			
	(a) Inventories	14	4,497.95	3,790.06
	(b) Trade Receivables	15	1,246.59	2,056.10
	(c) Cash and Cash Equivalents	16	321.15	344.53
	(d) Short-Term Loans and Advances	17	579.05	395.29
	TOTAL		9,226.76	9,298.99

The accompanying notes 1 to 34 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on behalf of Board of Directors
Deccan Health Care Limited

Keyur Shah
Proprietor
M.No. 153774

Minto P Gupta
Managing Director
DIN-00843784

Hitesh M Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 13th July, 2021

Mohak Gupta
Chief Financial Officer
PAN-ARTPG3989Q

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Statement of Profit & Loss for the Year ended on 31st March, 2021

(Rs. in lakhs)

	Particulars	Note No	For the Year Ended 31st March, 2021	For the Year Ended 31st March, 2020
I.	Revenue from Operations	18	3,377.58	4,224.41
II.	Other Incomes	19	5.54	5.72
III.	Total Revenue (I + II)		3,383.12	4,230.13
IV.	Expenses:			
	Cost of Materials Consumed	20	2,273.90	2,338.65
	Changes in Inventories of Finished Goods and Work-in-Progress	21	(430.88)	(663.78)
	Employee Benefit Expenses	22	291.76	433.38
	Depreciation and Amortization Expense	10	146.60	141.73
	Finance Costs	23	10.79	18.32
	Other Expenses	24	1,039.04	948.65
	Total Expenses		3,331.21	3,216.95
V.	Profit/ Loss before Exceptional Items and Tax (III - IV)		51.91	1,013.18
VI.	Exceptional Items			-
VII.	Profit before Tax (V-VI)		51.91	1,013.18
VIII.	Tax Expense:			
	(1) Provision for Income Tax			
	Income Tax		13.91	-
	Income Tax (MAT)		-	177.02
	Less: MAT Credit Entitlement		-	(177.02)
	(2) Deferred Tax		(0.99)	4.44
IX.	Profit/ (Loss) for the period (VII-VIII)		38.99	1,008.74
X.	Earnings Per Equity Share			
	(1) Basic	25	0.25	6.42
	(2) Diluted	25	0.25	6.42

The accompanying notes 1 to 34 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Place: Ahmedabad
Date : 13th July,2021

For & on behalf of Board of Directors
Deccan Health Care Limited

Minto P Gupta
Managing Director
DIN-00843784

Mohak Gupta
Chief Financial Officer
PAN-ARTPG3989Q

Hitesh M Patel
Director
DIN-02080625

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Cash Flow Statement for the Year Ended 31st March, 2021

(Rs. In Lakhs)

	PARTICULARS	For the Year Ended 31st March, 2021	For the Year Ended 31st March, 2020
A	Cash Flows from Operating Activities		
	Net Profit before tax and Extraordinary items	51.91	1,013.18
	Adjustments for :		
	Depreciation	146.60	141.73
	Interest Expense	10.79	18.32
	Interest Income	(0.76)	(1.36)
	Operating Profit before Working Capital Changes	208.54	1,171.87
	Adjustments for :		
	(Increase)/Decrease in Trade Receivables	809.51	(118.32)
	(Increase)/Decrease in Inventory	(707.90)	(580.65)
	Increase/(Decrease) in Provisions	8.31	25.87
	(Increase)/Decrease in Other Non Current Asset	(6.68)	(99.74)
	(Increase)/Decrease in Short Term Loans and Advances	(183.76)	(264.39)
	Increase/(Decrease) in Trade Payables	(140.33)	(65.01)
Increase/(Decrease) in Current Liabilities	48.04	198.75	
Cash Generated from Operations	35.73	268.38	
Tax Paid	(13.91)	-	
Net Cash from Operating Activities	21.82	268.38	
B	Cash Flows from Investing Activities		
	(Increase)/Decrease in Capital Work in Progress	(6.66)	-
	Purchase of Fixed Assets	(9.18)	(181.10)
	Interest Income	0.76	1.36
	(Increase)/Decrease in Non Current Investment	(1.00)	
	(Increase)/Decrease in Long Term Loans and Advances	7.91	(14.50)
Net Cash from Investing Activities	(8.17)	(194.24)	
C	Cash Flows from Financing Activities		
	Interest Expense	(10.79)	(18.32)
	Increase/(Decrease) in Long Term Borrowing	(26.24)	(159.12)
Net Cash from Investing Activities	(37.03)	(177.45)	
D	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(23.38)	(103.29)
E	Cash and Cash Equivalents at the beginning	344.53	447.82
F	Cash and Cash Equivalents at the end (D+E)	321.15	344.53

Note:

- Cash Flow Statement has been prepared using the indirect method in accordance with Accounting Standard AS 3-"Cash Flow Statement" notified under section 133 of the Companies Act,2013
- Represent Cash and Cash Equivalents as given in Note 16 to the Financial Statement.

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Place: Ahmedabad
Date : 13th July,2021

For & on behalf of Board of Directors
Deccan Health Care Limited

Minto P Gupta Hitesh M Patel
Managing Director Director
DIN-00843784 DIN-02080625

Mohak Gupta Sheena Jain
Chief Financial Officer Company Secretary
PAN-ARTPG3989Q PAN-BCJPJ9626H

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Standalone Notes to the Financial Statements as on 31st March, 2021

Note No: 1

A. Significant Accounting Policies:

The Accounting policies set out below have been adopted in preparation and presentation of financial statement and applied consistently to the period presented in this financial statement.

B. Disclosure of Accounting Policies:

a. Basis of Preparation:

These financial statement have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

b. Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles require the management to make estimates and assumptions that affect the reported amounts of Assets and Liabilities and disclosure of Contingent Liabilities at the date of the financial statements and the result of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Significant estimates used by the management in the preparation of these financial statements include provisions for bad and doubtful debts. Any revision to accounting estimates is recognized prospectively.

c. Accounting Convention and Revenue Recognition:

The Financial Statements have been prepared on a going concern basis in accordance with historical cost convention except for such fixed assets which are revalued. Both Income and Expenditure are recognized on accrual basis.

Revenue from Sales is recognized when practically all risks and rewards of ownership are transferred to the buyer and there is no effective control of the seller as the owner, this usually occurs upon dispatch of the goods. Gross sales shown in the Statement of Profit & Loss are inclusive of Excise duty but exclude discounts, CST, VAT & Goods & Service Tax. Net Sales are shown after deducting Excise duty which is disclosed at appropriate places. Interest income is recognized on receipt basis, and not on a time proportion basis, taking into accounts the amount outstanding and rate applicable.

Revenue are accounted Net of Goods & Service Tax (GST), Excise Duty, Taxes and Sales Returns. Other Items of Revenue are recognized in accordance with AS-9.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Standalone Notes to the Financial Statements as on 31st March, 2021

d. Cash Flow Statement: AS-3

The Company has prepared Cash Flow Statement as per the AS-3.

Cash flows are reported using the Indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

e. Retirements Benefits:

Staff benefits arising out of retirements / death, comprising of contributions to Provident Fund, Superannuation & Gratuity Schemes, accrued Leave Encashment and other post-separation benefits are accounted for on the basis of an independent actuarial valuation, in accordance with AS-15. The actuarial liability is determined with reference to employees at the end of each financial year.

Expenses for defined benefit gratuity payment plans are calculated as at the balance sheet date by independent actuaries in the manner that distributes expenses over the employees working life. These commitments are valued at the present value of the expected future payments, with consideration for calculated future salary increases, using a discounted rate corresponding to the interest rate estimated by the actuary having regard to the interest rate on Government Bonds with a remaining term i.e. almost equivalent to the average balance working period of employees.

The Company has adopted accounting standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed under the notes to financial Statement.

f. Property, Plant & Equipment:

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use, net charges on foreign exchange contracts and arrangements arising from exchange rate variations attributable to the assets. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow the entity and the cost can be measured reliably.

Depreciation on property, plant and equipment is provided using Straight Line Method over the useful life of the Asset. Depreciation in respect of addition to assets has been charged on pro rata basis with reference to the period of use of such asset.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of a property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Standalone Notes to the Financial Statements as on 31st March, 2021

g. Accounting for Investments:

Long term investments are stated at cost. However, provision for diminution is made to recognize any decline, other than temporary, in the value of long term investments. Current Investments are stated at the lower of cost and fair value.

h. Accounting for Intangible Assets:

Intangible assets are capitalized at cost if:

- a. It is probable that the future economic benefits that are attributable to the asset will flow to the company;
- b. The company will have control over the assets;
- c. The cost of these assets can be measured reliably and is more than 10,000/- & this is in accordance with AS-26.

i. Accounting for Borrowing Costs:

Borrowing cost relating to acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use/sale. Borrowing costs that are attributable to the projects are charged to the respective projects. All other borrowing costs, not eligible for capitalization, are charged to revenue accounts.

j. Accounting & Valuation for Inventories:

- i) Materials, Stores & Spares, Tools and Consumables are valued at Cost or Market Value, whichever is lower, on the basis of First In First Out method reflecting the fairest possible approximation to the cost incurred in bringing the items of Inventory to their present location and condition.
- ii) Finished Stock of completed products is valued at lower of Cost or Net Realizable Value on the basis of actual identified units. Cost being determined by including cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value determined by excluding all payable statutory dues and direct sales expenses.
- iii) Scrap is valued at Net Realizable Value.
- iv) Work in process in respect of activities is valued at estimated cost.

k. Accounting for Taxes on Income:

- i) Provision for tax for the year comprises current Income Tax and Deferred Tax and is provided as per the Income Tax Act, 1961.
- ii) Deferred tax resulting from timing differences between the book and the tax profits is accounted for, at the current rate of tax, to the extent that the timing differences are expected to crystallize. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in the future; however where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets/ liabilities are reviewed as at each balance sheet date.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Standalone Notes to the Financial Statements as on 31st March, 2021

l. Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

- i) The Company has a present obligation as a result of a past event;
- ii) A probable outflow of resources is expected to settle the obligation; and
- iii) The amount of the obligation can be reliably estimated.
- iv) Reimbursement expected in respect of expenditure required to settle a provision is recognized only when it is virtually certain that the reimbursement will be received.

Contingent Liability is disclosed in the case of:

- i) A present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation;
- ii) A possible obligation, unless the probability of outflow of resources is remote. Contingent Assets are neither recognized nor disclosed.

m. Earnings per Share:

The earnings considered in ascertaining the companies earning per share comprise net profit after tax and includes the post-tax effect of any extra-ordinary/exceptional item is considered. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the year.

The no. of shares used in computing diluted earnings per share comprises the weighted average no. of shares considered for deriving basic earnings per share and also the weighted average no. of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

n. Accounting for Impairment of Assets:

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired.

Impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of carrying amount over the higher of the asset's net sale price or present value as determined above.

o. Related Party Disclosures:

The Company as required by AS-18 furnishes the details of Related Party Disclosures in the notes to financial statements.

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

2 Share Capital

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Authorised Capital		
18000000 Equity Shares of Rs.10/- each (PY.18000000 Equity Share of Rs.10 /- each)	1,800.00	1,800.00
	1,800.00	1,800.00
Issued, Subscribed and Paid up		
1,57,13,430 Equity Shares of Rs.10/- each (PY.1,57,13,430 Equity Shares of Rs. 10/- each)	1,571.34	1,571.34
Total	1,571.34	1,571.34

A) The company has only one class of equity share having at par value of Rs.10/- per share.

B) During the year 31st March, 2021 ,the amount of share dividend recognised to equity share holder was "nil" (P.Y. "nil")

C) Reconciliation of number of shares outstanding and amount of share capital

Particulars	As at March 31, 2021		As at March 31, 2020	
	No. of Shares	Amounts	No. of Shares	Amounts
Shares outstanding at the beginning of the year	15,713,430	157,134,300	15,713,430	157,134,300
Shares issued during the year	-	-	-	-
Shares bought back during the year	-	-	-	-
Shares outstanding at the end of the year	15,713,430	157,134,300	15,713,430	157,134,300

D) Detail of shareholder holding more than 5% share in the company is given below :-

Particulars	As at March 31, 2021		As at March 31, 2020	
	No. of Shares held	% of holding	No. of Shares held	% of holding
Minto Pursottam Gupta	2,107,667	13.41	2,107,667	13.41
Meenakshi Gupta	1,671,333	10.64	1,707,333	10.87
Hitesh M Patel	1,798,014	11.44	3,009,214	19.15
Kent RO System Limited	968,800	6.17	968,800	6.17
Total	6,545,814	41.66	7,793,014	49.59

3 Reserves and Surplus

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Security Premium		
Opening Balance	5,373.59	5,373.59
Add: During the year	-	-
Less : Issue Exps / Transaction Cost regarding Inital Public Offer	-	-
Closing Balance (A)	5,373.59	5,373.59
Profit & Loss Account		
Opening balance	678.27	(330.47)
Add: Profit For the year	38.99	1,008.74
Less : Other Adjustment	-	-
Closing Balance (B)	717.26	678.27
Total(A+B)	6,090.87	6,051.86

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

4 Long Term Borrowings

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
(a) Term Loan (Secured)		
From Bank		
Axis Bank (Refer Note No. 33)	27.04	33.46
HDFC Bank - I (Refer Note No. 33)	18.11	25.80
HDFC Bank - II (Refer Note No. 33)	19.40	21.00
HDFC Bank - III (Refer Note No. 33)	13.67	16.43
HDFC Bank - IV (Refer Note No. 33)	3.73	
Kotak Mahindra Bank (Refer Note No. 33)	-	10.00
Less:- Current Maturity	(36.57)	(42.59)
	45.38	64.10
(b) Loan and Advances from Directors and Related Parties		
(i) From Directors	8.50	10.00
	8.50	10.00
(c) Loan from Member / Share Holders		
Value Worth Capital Management Pvt Ltd	12.75	12.75
	12.75	12.75
Total	66.63	86.85

5 Deffered Tax Liability

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Opening Balance of Deffered tax Laibility	213.68	209.23
Add: Provision for the year	(0.99)	4.44
Closing Balance of Deffered tax Laibility	212.68	213.68
Total	212.68	213.68

6 Long-Term Provisions

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Provision for Employee Benefits (Non Current)	14.08	15.38
Total	14.08	15.38

7 Trade Payables

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
- Due to Micro , Medium & Small Enterprises	-	-
- Others	565.64	705.97
Total	565.64	705.97

Note: The management is in process of identifying parites which are covered under MSME, The amount relating to MSME are disclosed to the extent identified.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Standalone Notes to the Financial Statement as at 31st March, 2021

8 Other Current Liabilities

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Current Maturities of Long-Term Debt	36.57	42.59
Advance from Customers	28.93	18.48
Duties & Taxes	72.52	77.14
Other Current Liabilities	367.43	325.23
Total	505.45	463.44

9 Short Term Provisions

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Provision for Employee Benefits	3.75	0.44
Provision for Income Tax	190.38	182.28
Provision for Others	5.94	7.75
Total	200.07	190.47

11 Long-Term Loans and Advances

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Security Deposits (Unsecured considered good)	20.28	28.19
Loans and advances to Related Parties	156.60	156.60
Total	176.87	184.78

12 Other Non Current Assets

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
R&D Product Development Expenses	236.92	224.61
TDS/ MAT recoverable	173.17	178.79
Total	410.08	403.40

13 Investment

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Investment in Subsidiary Co.		
Beyoungstore Private Limited	1.00	-
Total	1.00	-
Note Related to Investment:-		
(a) Aggregate Value of Quoted Investment:	-	-
(b) Market Value of Quoted Investment:	-	-
(c) Aggregate Amount of Unquoted Investment :	1.00	-

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

14 Inventories

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Raw Materials and Components	2,373.21	2,096.20
Work-in-Progress	1,667.03	1,184.12
Finished Goods	457.70	509.74
Total	4,497.95	3,790.06

15 Trade Receivables

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Unsecured, Considered Good		
- Outstanding for a period less than six months from the date they are due for payment	139.37	341.36
- Outstanding for a period exceeding six months from the date they are due for payment	1,107.23	1,714.75
Total	1,246.59	2,056.10

16 Cash and Cash Equivalents

(Rs. In Lakhs)

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Balances with banks (Inclusive of bank deposit)	12.06	10.08
Cash on hand/Imprest	309.09	334.45
Total	321.15	344.53

17 Short-Term Loans and Advances

Particulars	As at 31-03-2021 Rs.	As at 31-03-2020 Rs.
Advance To Creditors	576.11	391.52
Prepaid Exps	2.25	3.60
Other Current Assets	0.69	0.17
Total	579.05	395.29

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as on 31-03-2021

(Rs. In Lakhs)

10 Property, Plant & Equipments

SL NO	PARTICULARS	GROSS BLOCK			DEPRECIATION			NET BLOCK	
		AS AT 01.04.2020	ADDITIONS DURING THE YEAR	TOTAL AS AT 31.03.2021	UPTO 01.04.2020	FOR THE YEAR	UPTO 31.03.2021	NET CARRYING AMOUNT AS AT 31.03.2021	NET CARRYING AMOUNT AS AT 31.03.2020
1	Land (Lease Hold)	28.41	-	28.41	-	-	-	28.41	28.41
2	Factory Building	1,432.97	-	1,432.97	306.91	47.86	354.78	1,078.20	1,126.06
3	Plant & Machinery	1,154.34	0.58	1,154.92	558.92	54.84	613.76	541.17	595.42
4	R&D (Machinery)	85.96	-	85.96	33.08	4.08	37.16	48.79	52.88
5	Furniture & Fixture	102.58	2.35	104.93	65.83	6.61	72.44	32.49	36.75
6	Electrical Appliances	47.62	0.37	47.99	4.99	2.27	7.26	40.73	42.63
7	Computer & Software	100.85	1.82	102.67	95.50	3.00	98.50	4.17	5.35
8	Office Equipments	42.92	0.10	43.02	19.16	2.72	21.88	21.14	23.76
9	Air Conditions	15.41	-	15.41	9.07	0.98	10.04	5.37	6.35
10	Vehicles	340.16	3.97	344.13	132.94	24.24	157.18	186.95	207.22
	Sub Total	3,351.23	9.18	3,360.41	1,226.40	146.60	1,373.00	1,987.41	2,124.83
	Previous Year	3,170.13	181.10	3,351.23	1,084.67	141.73	1,226.40	2,124.83	2,085.46

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

18 Revenue From Operation

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Sale of Products - Domestic	3,369.76	4,224.41
- Export	7.82	-
Total	3,377.58	4,224.41

19 Other Incomes

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Interest Income	0.76	1.36
Discount Received	0.25	1.54
Balances Written off	2.19	-
Other Non-Operating Income	2.34	2.82
Total	5.54	5.72

20 Cost of Material Consumed

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Opening Stock	2,096.20	2,179.33
Purchases	2,550.91	2,255.52
Less Closing Stock	2,373.21	2,096.20
Total	2,273.90	2,338.65

21 Changes in Inventories of Finished Goods and Work-in-Progress

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Opening Stock (Finished Goods & WIP)	1,693.86	1,030.08
Closing Stock (Finished Goods & WIP)	2,124.74	1,693.86
Total	(430.88)	(663.78)

22 Employee Benefit Expenses

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Salaries and Wages	275.10	413.90
Contribution to Provident Fund and Other funds & Staff Welfare Exps	16.66	19.47
Total	291.76	433.38

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

23 Finance Costs

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Interest On Long Term Borrowing	7.61	12.71
Interest On others	-	1.20
Other Borrowing Charges	3.18	4.41
Total	10.79	18.32

24 Other Expenses

(Rs. In Lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.	For The Year Ended on 31-03-2020 Rs.
Administration Charges	8.08	20.86
Auditors' Remuneration	2.50	2.50
Casual Labour Charges & Wages	82.36	41.54
Communication, Courier & Telephone Expenses	10.64	11.07
Consumable & Manufacturing Expenses	6.71	5.59
Directors Sitting Fees	0.15	0.25
Freight , Cartage & Packing	18.01	29.49
Licenses & Fees	6.77	3.95
Membership Expenses	1.12	0.77
Misc Expenses	-	2.43
Power & Fuel	41.56	55.57
Professional & Legal Expenses	7.71	40.45
R&D Expenses	4.73	57.08
Rent, Rates & Taxes	27.87	69.62
Repair & Maintenance Expenses	26.03	17.44
Security Expenses	6.37	9.44
Selling & Distribution Expenses	677.26	519.30
Software and Hardware Expenses	3.10	7.14
Stationery & Printing Expenses	1.83	4.07
Travelling & Conveyance Expenses	10.68	50.07
Balances Written off	95.57	-
Total	1,039.04	948.65

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

- 25 In compliance to Accounting Standard 20 on "Earning per share", the calculation of Earnings per Share (Basic and diluted) is as under:

(Rs. In Lakhs)

Particulars	Year ended 31.03.2021	Year ended 31.03.2020
A. Profit/Loss attributable to Equity Shareholders	38.99	1,008.74
B. Weighted average No. of Shares	15,713,430	15,713,430
C. Nominal value of equity share	10	10
D. Basic EPS (Rs.) (A)/(B)	0.25	6.42
E. Diluted EPS(Rs.)	0.25	6.42

- 26 **Contingent Liabilities:-**
Contingent Liabilities, not provided for:
(As Certified by the Management)

(Rs. In Lakhs)

Particulars	Year ended 31.03.2021	Year ended 31.03.2020
Corporate Social Responsibility	67.13	50.32
Income Tax Law	1,497.45	1,000.38

- 27 In the opinion of the Management, Current Assets, Loans and Advances shall have the value on realization, in the ordinary course of the business, equal to the amount at which they are stated in the Balance Sheet.
- 28 In compliance of Accounting Standard 17 (AS-17) on "Segment Reporting" as notified under Companies Accounting Standard Rules, 2006, the company is engaged in manufacturing of Fast Moving Consumer Health Products (FMCHP). Considering the nature of business and financial reporting of the company, the company is operating only one segment and hence the segment reporting is not applicable.
- 29 The Company has adopted Accounting Standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed as under :

(Rs. in Lakhs)

1. Amount of Liability in respect of Gratuity		
Particulars	FY 2020-21	FY 2019-20
Opening Balance of Obligation	15.82	17.88
Add :-		
Current Service Cost	3.26	3.82
Past Service Cost	-	-
Interest Cost	1.03	1.25
Benefits Paid	-	-
Actuarial Gain (Loss)	(2.27)	(7.13)
Closing Balance	17.84	15.82

2. Amount of obligation recognized in statement of		
Particulars	FY 2020-21	FY 2019-20
Current Service Cost	3.26	3.82
Past Service Cost	-	-
Interest Cost	1.03	1.25
Expected Return on plan assets	-	-
Net Actuarial Losses (Gain) Recognised in the Year	(2.27)	(7.13)
Expenses Recognised In Statement of Profit & Loss	2.01	(2.06)

- 30 Previous years' figures are restated or regrouped or rearranged wherever necessary in order to confirm to the current years' grouping and classifications.
- 31 The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. In many countries, businesses are being forced to cease or limit their operations for long or indefinite period of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses, resulting in an economic slowdown.

In assessing the recoverability of Company's assets such as Investments, Loans, intangible assets, Goodwill, Trade receivable, Inventories etc. the Company has considered internal and external information upto the date of approval of these Financial Statements. The company has performed sensitivity analysis on the assumptions used basis the internal and external information / indicators of future economic conditions and expects to recover the carrying amount of the assets and management has assessed, as a part of going concern assessment, impact of current event regarding COVID-19 and on entity's operations and forecasted cash flow and management has a positive view regarding the operations of the company.

32 Additional Information

a) Reporting under Micro, small & Medium Enterprise Development Act, 2016

The Company has initiated the process of identification of Creditors which falls under category of MSME, the disclosure relating to amount due to MSME are made to the extent information received.

b) Payment to auditor

	For the year ended on 31st March, 2021 (Rs. in Lakhs)	For the year ended on 31st March, 2020 (Rs. in Lakhs)
Payment to Statutory Auditor as		
Audit Fees	2.50	2.50

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

33 Details of Long Term Borrowings (Secured)

Sr. No.	Lender	Nature of facility	Loan Amount	Amount outstanding as at March 31, 2021	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Axis Bank	Car Loan	Rs. 69.00 Lakhs	Rs. 27.04 Lakhs	9.15%	Repayable in 60 Monthly Installment of Rs.1,43,735/- Each	Hypothication of BMW car Purchased through Loan
2	HDFC Bank-I	Car Loan	Rs. 52.13 Lakhs	Rs.18.11 Lakhs	10.00%	Repayable in 60 Monthly Installment of Rs.1,10,787/- Each	Hypothication of Benz car Purchased through Loan
3	HDFC Bank-II	Car Loan	Rs. 21.25 Lakhs	Rs.19.40 Lakhs	13.50%	Repayable in 60 Monthly Installment of Rs.48,900/- Each	Hypothication of Mercedes car Purchased through Loan
4	HDFC Bank-III	Car Loan	Rs. 18.14 Lakhs	Rs.13.67 Lakhs	9.50%	Repayable in 60 Monthly Installment of Rs.38,087/- Each	Hypothication of Toyota car Purchased through Loan
5	HDFC Bank-IV	Car Loan	Rs. 4.13 Lakhs	Rs. 3.73 Lakhs	8.50%	Repayable in 60 Monthly Installment of Rs.8434/- Each	Hypothication of Maruti Eco car Purchased through Loan
6	Kotak Mahindra Bank	Car Loan	Rs. 85.00 Lakhs	-	8.25%	Repayable in 36 Monthly Installment of Rs. 2,67,708/- Each	Hypothication of Porsche car Purchased through Loan

DECCAN HEALTH CARE LIMITED

CIN: L72200TG1996PLC024351

247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082

Standalone Notes to the Financial Statement as at 31st March, 2021

Sr. No.	Nature of Transaction	Associates/Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'20 to March'21	April'20 to March'21
2	<u>Unsecured Loan</u>		
	<u>Hitesh N. Patel</u>		
	Loan accepted	--	50.00
	Loan repaid	--	50.00
	<u>Yezdi Jal Batliwala</u>		
	Loan accepted	--	--
	Loan repaid	--	1.50
	<u>Mohita Gupta</u>		
	Loan accepted	--	40.00
	Loan repaid	--	40.00
3	<u>Loans & Advances</u>		
	<u>Beyoung Store Private Limited</u>		
	Loan accepted		0.89
	Loan repaid		1.03
4	<u>Investment</u>		
	<u>Beyoung Store Private Limited</u>		1.00

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Place: Ahmedabad
Date : 13th July,2021

For & on behalf of Board of Directors
Deccan Health Care Limited

Minto P Gupta
Managing Director
DIN-00843784

Mohak Gupta
Chief Financial Officer
PAN-ARTPG3989Q

Hitesh M Patel
Director
DIN-02080625

Sheena Jain
Company Secretary
PAN-BCJPJ9626H

INDEPENDENT AUDITOR'S REPORT

**To
The Members of
DECCAN HEALTH CARE LIMITED**

Report on the Audit of the Consolidated Financial Statements

Opinion

We have audited the accompanying Consolidated Financial Statements of **DECCAN HEALTH CARE LIMITED** (hereinafter referred to as the "Holding Company") and its subsidiaries (Holding Company and its Subsidiaries together referred to as "the Group"), which comprise the Consolidated Balance sheet as at 31st March, 2021, and the Consolidated statement of Profit and Loss, and Consolidated Statement of Cash flows Statement for the year then ended, and Notes to the Consolidated Financial Statements, including a summary of significant accounting policies (hereinafter referred to as "the Consolidated Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Consolidated Financial Statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of their consolidated state of affairs of the Company as at March 31, 2021, and Consolidated Profit/Loss, and its Consolidated Cash Flows for the year then ended.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Consolidated Financial Statements* section of our report. We are independent of the Group in accordance with the *Code of Ethics* issued by the Institute of Chartered Accountants of India, and we have fulfilled our other ethical responsibilities in accordance with the provision of Companies Act, 2013. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon and we do not provide a separate opinion on these matters and there is no any Key Audit Matters which need to be reported.

Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

The Holding Company's Board of Directors is responsible for the preparation and presentation of these Consolidated Financial Statements in terms of the requirements of the Companies Act, 2013 that give a true and fair view of the Consolidated financial position and Consolidated financial

performance, of the Group in accordance with the accounting principles generally accepted in or outside of India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the Company included in the Group is responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Consolidated Financial Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the Consolidated Financial Statements, the respective Board of Directors of the Company included in the Group is responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group is responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the Consolidated Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Consolidated Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Consolidated Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Consolidated Financial Statements, including the disclosures, and whether the Consolidated Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the Consolidated Financial Statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the Consolidated Financial Statements of which we are Independent Auditors. For the other entities included in the Consolidated Financial Statements, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audit carried out by them. We remain solely responsible for our audit opinion.

We communicate with those charged with governance of the Holding Company and such other entities included in the Consolidated Financial Statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Report on other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report, to the extent applicable, that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid Consolidated Financial Statements.

- (b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid Consolidated Financial Statement have been kept so far as it appears from our examination of those books and the reports of the other auditors.
- (c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of the consolidated financial statement.
- (d) In our opinion, the aforesaid Consolidated Financial Statements comply with the Accounting Standards specified under Section 133 of the Act.
- (e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2021 taken on record by the Board of Directors of the Holding Company and the reports of the statutory of its subsidiary companies incorporated in India, none of the directors of the Group companies incorporated in India is disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate Report in “Annexure A”.
- (g) With respect to the other matters to be included in the Auditor’s Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
- i. The Company has disclosed the impact of pending litigation which should require to disclose on its financial position.
 - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
 - iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company.

For Keyur Shah & Co.
Chartered Accountants
FRN.: 141173W

Keyur Shah
Proprietor
Membership No.: 153774
UDIN –21153774AAAAEN4945

Date: 13-07-2021
Place: Ahmedabad

“Annexure A” to the Independent Auditor’s Report of even date on the Consolidated Financial Statements of **DECCAN HEALTH CARE LIMITED**

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of Section 143 of the Companies Act, 2013 (“the Act”)

In conjunction with our audit of the Consolidated Financial Statements of Network People Services Technologies limited as of and for the year ended March 31, 2021, we have audited the internal financial controls over financial reporting of Deccan Health Care Limited (hereinafter referred to as the “Holding Company”) and its subsidiaries, which are companies incorporated in India, as of that date.

Management’s Responsibility for Internal Financial Controls

The respective Board of Directors of the Holding Company, its subsidiaries, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective Company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

Auditor’s Responsibility

Our responsibility is to express an opinion on the Holding Company, its subsidiaries, which are companies incorporated in India, internal financial controls over financial reporting with reference to these Consolidated Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, both, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors’ judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports referred to in the Other Matters paragraph below, is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements.

Meaning of Internal Financial Controls over Financial Reporting With Reference to these Consolidated Financial Statements

A Company's internal financial control over financial reporting with reference to these Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A Company's internal financial control over financial reporting with reference to these Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Inherent Limitations of Internal Financial Controls over Financial Reporting With Reference to these Consolidated Financial Statements

Because of the inherent limitations of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Consolidated Financial Statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Opinion

In our opinion, to the best of our information and according to the explanations given to us, the Holding Company, its subsidiaries, which are companies incorporated in India, have, maintained in all material respects, adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements and such internal financial controls over financial reporting with reference to these Consolidated Financial Statements were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For Keyur Shah & Co.
Chartered Accountants
FRN.: 141173W

Keyur Shah
Proprietor
Membership No.: 153774
UDIN – 21153774AAAAEN4945

Date: 13-07-2021
Place: Ahmedabad

	Particulars	Note No.	As at 31st March, 2021
I.	EQUITY AND LIABILITIES		
(1)	Shareholder's Funds		
	(a) Share Capital	2	1,571.34
	(b) Reserves and Surplus	3	6,090.87
(2)	Share Application Money pending allotment		
(3)	Non-Current Liabilities		
	(a) Long-Term Borrowings	4	66.63
	(b) Deferred Tax Liability	5	212.68
	(c) Long Term Provisions	6	14.08
(4)	Current Liabilities		
	(a) Trade Payables	7	565.64
	(b) Other Current Liabilities	8	505.45
	(c) Short-Term Provisions	9	200.08
	TOTAL		9,226.77
II.	ASSETS		
(1)	Non-Current Assets		
	(a) Fixed Assets		
	(i) Tangible Assets	10	1,987.41
	(ii) Intangible Assets		-
	(iii) Intangible Assets Under Development		6.66
	(b) Long-Term Loans and Advances	11	176.87
	(c) Other Non-Current Assets	12	410.08
(2)	Current Assets		
	(a) Inventories	13	4,497.95
	(b) Trade Receivables	14	1,246.59
	(c) Cash and Cash Equivalent	15	322.26
	(d) Short-Term Loans and Advances	16	578.95
	TOTAL		9,226.77

The accompanying notes 1 to 33 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on Behalf of Board of Directors

Keyur Shah
Proprietor
M.No. 153774

Minto P. Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 13th July, 2021

Mohak Gupta
C.F.O.
PAN- ARTPG3989Q

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Consolidated Profit & Loss for the Year ended on 31st March, 2021

(Rs. in lakhs)

	Particulars	Note No	For the Year Ended 31st March, 2021 Audited
I.	Revenue from Operations	17	3,377.58
II.	Other Incomes	18	5.54
III.	Total Revenue (I + II)		3,383.12
IV.	Expenses:		
	Cost of Materials Consumed	19	2,273.90
	Changes in Inventories of Finished Goods and Work-in-Progress	20	(430.88)
	Employee Benefit Expenses	21	291.76
	Depreciation and Amortization Expense	10	146.60
	Finance Costs	22	10.79
	Other Expenses	23	1,039.04
	Total Expenses		3,331.21
V.	Profit/ Loss before Exceptional Items and Tax (III - IV)		51.91
VI	Exceptional Items		
VII	Profit before Tax (V-VI)		51.91
VIII	Tax Expense:		
	(1) Provision for Income Tax		
	Income Tax		13.91
	Income Tax (MAT)		-
	Less: MAT Credit Entitlement		-
	(2) Deferred Tax		(0.99)
IX	Profit/ (Loss) for the period (VII-VIII)		38.99
X	Earnings Per Equity Share		
	(1) Basic	24	0.25
	(2) Diluted	24	0.25

The accompanying notes 1 to 33 form an integral part of the Financial Statements

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on behalf of Board of Directors

Keyur Shah
Proprietor
M.No. 153774

Minto P. Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 13th July, 2021

Mohak Gupta
C.F.O.
PAN- ARTPG3989Q

Sheena Jain
Company Secretary
PAN-BCJPJ9626H



DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Consolidated Cash Flow Statement for the Year Ended 31st March, 2021

(Rs. in lakhs)

	PARTICULARS	For the Year Ended 31st March, 2021
A	Cash Flows from Operating Activities	
	Net Profit before tax and Extraordinary items	51.91
	Adjustments for :	
	Depreciation	146.60
	Interest Expense	10.79
	Interest Income	(0.76)
	Operating Profit before Working Capital Changes	208.54
	Adjustments for :	
	(Increase)/Decrease in Trade Receivables	809.51
	(Increase)/Decrease in Inventory	(707.90)
	Increase/(Decrease) in Provisions	8.31
	(Increase)/Decrease in Non Current Asset	(6.68)
	(Increase)/Decrease in Short Term Loans and Advances	(183.65)
	Increase/(Decrease) in Trade Payables	(140.33)
	Increase/(Decrease) in Current Liabilities	48.04
	Cash Generated from Operations	35.84
	Tax Paid	(13.91)
	Net Cash from Operating Activities	21.93
B	Cash Flows from Investing Activities	
	(Increase)/Decrease in CWIP	(6.66)
	Purchase of Fixed Assets	(9.18)
	Interest Income	0.76
	(Increase)/Decrease in Long Term Loans and Advances	7.91
	Net Cash from Investing Activities	(7.17)
C	Cash Flows from Financing Activities	
	Interest Expense	(10.79)
	Increase/(Decrease) in Long Term Borrowing	(26.24)
	Net Cash from Investing Activities	(37.03)
D	Net Increase/(Decrease) in Cash and Cash Equivalents (A+B+C)	(22.27)
E	Cash and Cash Equivalents at the beginning	344.53
F	Cash and Cash Equivalents at the end (D+E)	322.26

Note:

- Cash Flow Statement has been prepared using the indirect method in accordance with Accounting Standard AS 3-"Cash Flow Statement" notified under section 133 of the Companies Act,2013
- Represent Cash and Cash Equivalents as given in Note 15 to the Financial Statement.

As per our Report of even date attached

For & on behalf of Board of Directors

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

Keyur Shah
Proprietor
M.No. 153774

Minto P. Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 13th July, 2021

Mohak Gupta
C.F.O.
PAN- ARTPG3989Q

Sheena Jain
Company Secretary
PAN-BCJPJ9626H

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Consolidated Notes to the Financial Statements as on 31st March, 2021

Note No: 1

A. Significant Accounting Policies:

The Accounting policies set out below have been adopted in preparation and presentation of financial statement and applied consistently to the period presented in this financial statement.

B. Disclosure of Accounting Policies:

a. Basis of Preparation:

These financial statement have been prepared to comply in all material aspects with applicable accounting principles in India, the applicable accounting standards prescribed under section 133 of the Companies Act, 2013 ('Act') read with Rule 7 of the Companies (Accounts) Rules, 2014, the provisions of the Act (to the extent notified) and other accounting principles generally accepted in India, to the extent applicable. The accounting policies have been consistently applied by the Company and are consistent with those used in the previous year.

b. Principles of Consolidation:

The Consolidated Restated financial statements relate to Deccan Health Care Limited ("the Company") and its subsidiary entity viz Beyoungstore Private Limited. The Consolidated Financial Statements have been prepared on following basis:

- I. The financial statements of the company and its subsidiary entity, used in the consolidation are drawn up to the same date as that of the company i.e. 31st March 2021.
- II. The financial statements of the Company and its subsidiary entity have been combined on line-by-line basis by adding together like items of assets, liabilities, income and expenses, after eliminating intra-group balances, intra-group transactions and resulting unrealized profit or losses, unless cost cannot be recovered.
- III. The excess of cost to the company of its investment in the subsidiary entity over its share of equity of the subsidiary entity, at the date on which the investment in the subsidiary entity were made, is recognized as 'Goodwill' being an asset in the consolidated financial statement and is tested for impairment on annual basis.
- IV. Goodwill arising on consolidation is not amortized but tested for impairment.
- V. The consolidated financial statement have been prepared using uniform accounting policies for like transactions and other events in similar circumstances and are presented to the extent possible, in the same manner as the company's separate financial statements.
- VI. Following subsidiary company/entity, associate and jointly controlled entities have been considered in the preparation of the consolidated financial statement:

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Consolidated Notes to the Financial Statements as on 31st March, 2021

Name of the Company	Relationship	Country of Incorporation	% of Holding and voting power either directly or indirectly through subsidiary (As at 31 st March, 2021)
Beyoung Store Private Limited	Subsidiary	India	99.99%

c. Use of Estimates:

The preparation of financial statements in conformity with generally accepted accounting principles require the management to make estimates and assumptions that affect the reported amounts of Assets and Liabilities and disclosure of Contingent Liabilities at the date of the financial statements and the result of operations during the reporting period. Although these estimates are based upon management's best knowledge of current events and actions, actual results could differ from these estimates. Significant estimates used by the management in the preparation of these financial statements include provisions for bad and doubtful debts. Any revision to accounting estimates is recognized prospectively.

d. Accounting Convention and Revenue Recognition:

The Financial Statements have been prepared on a going concern basis in accordance with historical cost convention except for such fixed assets which are revalued. Both Income and Expenditure are recognized on accrual basis.

Revenue from Sales is recognized when practically all risks and rewards of ownership are transferred to the buyer and there is no effective control of the seller as the owner, this usually occurs upon dispatch of the goods. Gross sales shown in the Statement of Profit & Loss are inclusive of Excise duty but exclude discounts, CST, VAT & Goods & Service Tax. Net Sales are shown after deducting Excise duty which is disclosed at appropriate places. Interest income is recognized on receipt basis, and not on a time proportion basis, taking into accounts the amount outstanding and rate applicable.

Revenue are accounted Net of Goods & Service Tax (GST), Excise Duty, Taxes and Sales Returns. Other Items of Revenue are recognized in accordance with AS-9.

e. Cash Flow Statement: AS-3

The Company has prepared Cash Flow Statement as per the AS-3.

Cash flows are reported using the Indirect method, whereby net profit before tax is adjusted for the effects of transactions of a non cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the group are segregated.

f. Retirements Benefits:

Staff benefits arising out of retirements / death, comprising of contributions to Provident Fund, Superannuation & Gratuity Schemes, accrued Leave Encashment and other post-separation benefits are accounted for on the basis of an independent actuarial valuation, in accordance with AS-15. The actuarial liability is determined with reference to employees at the end of each financial year.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Consolidated Notes to the Financial Statements as on 31st March, 2021

Expenses for defined benefit gratuity payment plans are calculated as at the balance sheet date by independent actuaries in the manner that distributes expenses over the employees working life. These commitments are valued at the present value of the expected future payments, with consideration for calculated future salary increases, using a discounted rate corresponding to the interest rate estimated by the actuary having regard to the interest rate on Government Bonds with a remaining term i.e. almost equivalent to the average balance working period of employees.

The Company has adopted accounting standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed under the notes to financial Statement.

g. Property, Plant & Equipment:

Property, plant and equipment are stated at cost, net of recoverable taxes, trade discount and rebates less accumulated depreciation and impairment losses, if any. Such cost includes purchase price, borrowing cost and any cost directly attributable to bringing the assets to its working condition for its intended use, net charges on foreign exchange contracts and arrangements arising from exchange rate variations attributable to the assets. Expenditure on additions, improvements and renewals is capitalized and expenditure for maintenance and repairs is charged to profit and loss account.

Subsequent costs are included in the asset's carrying amount or recognized as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow the entity and the cost can be measured reliably.

Depreciation on property, plant and equipment is provided using Straight Line Method over the useful life of the Asset. Depreciation in respect of addition to assets has been charged on pro rata basis with reference to the period of use of such asset.

The residual values, useful lives and methods of depreciation of property, plant and equipment are reviewed at each financial year end and adjusted prospectively, if appropriate.

Gains or losses arising from de recognition of a property, plant and equipment are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognized in the Statement of Profit and Loss when the asset is derecognized

h. Accounting for Investments:

Long term investments are stated at cost. However, provision for diminution is made to recognize any decline, other than temporary, in the value of long term investments. Current Investments are stated at the lower of cost and fair value.

i. Accounting for Intangible Assets:

Intangible assets are capitalized at cost if:

- a. It is probable that the future economic benefits that are attributable to the asset will flow to the company;
- b. The company will have control over the assets;
- c. The cost of these assets can be measured reliably and is more than 10,000/- & this is in accordance with AS-26.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Consolidated Notes to the Financial Statements as on 31st March, 2021

j. Accounting for Borrowing Costs:

Borrowing cost relating to acquisition/ construction of qualifying assets are capitalized until the time all substantial activities necessary to prepare the qualifying assets for their intended use are complete. A qualifying asset is one that necessarily takes substantial period of time to get ready for its intended use/sale. Borrowing costs that are attributable to the projects are charged to the respective projects. All other borrowing costs, not eligible for capitalization, are charged to revenue accounts.

k. Accounting & Valuation for Inventories:

- i) Materials, Stores & Spares, Tools and Consumables are valued at Cost or Market Value, whichever is lower, on the basis of First In First Out method reflecting the fairest possible approximation to the cost incurred in bringing the items of Inventory to their present location and condition.
- ii) Finished Stock of completed products is valued at lower of Cost or Net Realizable Value on the basis of actual identified units. Cost being determined by including cost of purchase, cost of conversion and other costs incurred in bringing the inventories to their present location and condition. Net realizable value determined by excluding all payable statutory dues and direct sales expenses.
- iii) Scrap is valued at Net Realizable Value.
- iv) Work in process in respect of activities is valued at estimated cost.

l. Accounting for Taxes on Income:

- i) Provision for tax for the year comprises current Income Tax and Deferred Tax and is provided as per the Income Tax Act, 1961.
- ii) Deferred tax resulting from timing differences between the book and the tax profits is accounted for, at the current rate of tax, to the extent that the timing differences are expected to crystallize. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in the future; however where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is a virtual certainty of realization of such assets. Deferred tax assets/ liabilities are reviewed as at each balance sheet date.

m. Provisions, Contingent Liabilities and Contingent Assets:

Provisions are recognized for liabilities that can be measured only by using a substantial degree of estimation, if

- i) The Company has a present obligation as a result of a past event;
- ii) A probable outflow of resources is expected to settle the obligation; and
- iii) The amount of the obligation can be reliably estimated.
- iv) Reimbursement expected in respect of expenditure required to settle a provision is recognized only when it is virtually certain that the reimbursement will be received.

DECCAN HEALTH CARE LIMITED
CIN: L72200TG1996PLC024351
247 2nd Floor Dwarakapuri Colony Punjagutta Hyderabad TG-500082
Consolidated Notes to the Financial Statements as on 31st March, 2021

Contingent Liability is disclosed in the case of:

- i) A present obligation arising from a past event, when it is not probable that an outflow of resources will be required to settle the obligation;
- ii) A possible obligation, unless the probability of outflow of resources is remote. Contingent Assets are neither recognized nor disclosed.

n. Earnings per Share:

The earnings considered in ascertaining the companies earning per share comprise net profit after tax and includes the post-tax effect of any extra-ordinary/exceptional item is considered. The number of shares used in computing basic earnings per share is the weighted average number of shares outstanding during the year.

The no. of shares used in computing diluted earnings per share comprises the weighted average no. of shares considered for deriving basic earnings per share and also the weighted average no. of equity shares that could have been issued on the conversion of all dilutive potential equity shares.

o. Accounting for Impairment of Assets:

Management periodically assesses using external and internal sources whether there is an indication that an asset may be impaired.

Impairment occurs where the carrying value exceeds the present value of future cash flows expected to arise from the continuing use of the asset and its eventual disposal. The impairment loss to be expensed is determined as the excess of carrying amount over the higher of the asset's net sale price or present value as determined above.

p. Related Party Disclosures:

The Company as required by AS-18 furnishes the details of Related Party Disclosures in the notes to financial statements.

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

2 Share Capital

(Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Authorised Capital	
18000000 Equity Shares of Rs.10/- each (PY.18000000 Equity Share of Rs.10 /- each)	1,800.00
	1,800.00
Issued, Subscribed and Paid up	
1,57,13,430 Equity Shares of Rs.10/- each (PY.1,57,13,430 Equity Shares of Rs. 10/- each)	1,571.34
Total	1,571.34

A) The company has only one class of equity share having at par value of Rs.10/- per share.

B) During the year 31st March, 2021 ,the amount of share dividend recognised to euuity share holder was "nil" (P.Y. "nil")

C) Reconciliation of number of shares outstanding and amount of share capital

Particulars	As at March 31, 2021	
	No. of Shares	Amounts
Shares outstanding at the beginning of the year	15,713,430	157,134,300
Shares issued duing the year	-	-
Shares bought back during the year	-	-
Shares outstanding at the end of the year	15,713,430	157,134,300

D) Detail of shareholder holding more than 5% share in the company is given below :-

Particulars	As at March 31, 2021	
	No. of Shares held	% of holding
Minto Pursottam Gupta	2,107,667.00	13.41
Meenakshi Gupta	1,671,333.00	10.64
Hitesh M Patel	1,798,014.00	11.44
Kent RO System Limited	968,800.00	6.17
Total	6,545,814.00	41.66

3 Reserves and Surplus

(Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Security Premium	
Opening Balance	5,373.59
Add: During the year	
Less : Issue Exps / Transaction Cost regarding Initail Public Offer	
Closing Balance (A)	5,373.59
Profit & Loss Account	
Opening balance	678.27
Add: Profit For the year	39.01
Less : Other Adjustment	-
Closing Balance (B)	717.28
Total(A+B)	6,090.87

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

4 Long Term Borrowings (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
(a) Term Loan (Secured)	
From Bank	
Axis Bank (Refer Note No. 32)	27.04
HDFC Bank - I (Refer Note No. 32)	18.11
HDFC Bank - II (Refer Note No. 32)	19.40
HDFC Bank - III (Refer Note No. 32)	13.67
HDFC Bank - IV (Refer Note No. 32)	3.73
Less:- Current Maturity	(36.57)
	45.38
(b) Loan and Advances from Directors and Related Parties	
(i) From Directors	8.50
	8.50
(c) Loan from Member / Share Holders	
Value Worth Capital Management Pvt Ltd	12.75
	12.75
Total	66.63

5 Deffered Tax Liability (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Opening Balance of Deffered tax Laibility	213.68
Add: Provision for the year	(1.00)
Closing Balance of Deffered tax Laibility	212.68
Total	212.68

6 Long-Term Provisions (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Provision for Employee Benefits (Non Current)	14.08
Total	14.08

7 Trade Payables (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
- Due to Micro , Medium & Small Enterprises	-
- Others	565.64
Total	565.64

Note: The management is in process of identifying parites which are covered under MSME, The amount relating to MSME are disclosed to the extent identified.

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

8 Other Current Liabilities (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Current Maturities of Long-Term Debt	36.57
Advance from Customers	28.93
Duties & Taxes	72.52
Other Current Liabilities	367.43
Total	505.45

9 Short Term Provisions (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Provision for Employee Benefits	3.75
Provision for Income Tax	190.38
Provision for Others	5.95
Total	200.08

11 Long-Term Loans and Advances (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Security Deposits (Unsecured considered good)	20.27
Loans and advances to Related Parties	156.60
Total	176.87

12 Other Non Current Assets (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
R&D Product Development Expenses	236.92
TDS/ MAT recoverable	173.16
Total	410.08

13 Inventories (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Raw Materials and Components	2,373.21
Work-in-Progress	1,667.04
Finished Goods	457.70
Total	4,497.95

Note: Inventories are certified by the management

14 Trade Receivables (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Unsecured, Considered Good	
- Outstanding for a period less than six months from the date they are due for payment	139.37
- Outstanding for a period exceeding six months from the date they are due for payment	1,107.22
Total	1,246.59

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

15 Cash and Cash Equivalents (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Balances with banks (Inclusive of Bank Deposit)	13.16
Cash on hand/Imprest	309.10
Total	322.26

16 Short-Term Loans and Advances (Rs. in lakhs)

Particulars	As at 31-03-2021 Rs.
Advance To Creditors	576.11
Prepaid Exps	2.24
Other Current Assets	0.60
Total	578.95

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Consolidated Depreciation Schedule for the Year ended 31-03-2021

(Rs. In Lakhs)

10 Fixed Assets

SL NO	PARTICULARS	GROSS BLOCK			DEPRECIATION			NET BLOCK	
		AS AT 01.04.2020	ADDITIONS DURING THE YEAR	TOTAL AS AT 31.03.2021	UPTO 01.04.2020	FOR THE YEAR	UPTO 31.03.2021	NET CARRYING AMOUNT AS AT 31.03.2021	NET CARRYING AMOUNT AS AT 31.03.2020
1	Land (Lease Hold)	28.41	-	28.41	-	-	-	28.41	28.41
2	Factory Building	1,432.97	-	1,432.97	306.91	47.86	354.78	1,078.20	1,126.06
3	Plant & Machinery	1,154.34	0.58	1,154.92	558.92	54.84	613.76	541.17	595.42
4	R&D (Machinery)	85.96	-	85.96	33.08	4.08	37.16	48.79	52.88
5	Furniture & Fixture	102.58	2.35	104.93	65.83	6.61	72.44	32.49	36.75
6	Electrical Appliances	47.62	0.37	47.99	4.99	2.27	7.26	40.73	42.63
7	Computer & Software	100.85	1.82	102.67	95.50	3.00	98.50	4.17	5.35
8	Office Equipments	42.92	0.10	43.02	19.16	2.72	21.88	21.14	23.76
9	Air Conditions	15.41	-	15.41	9.07	0.98	10.04	5.37	6.35
10	Vehicles	340.16	3.97	344.13	132.94	24.24	157.18	186.95	207.22
	Sub Total	3,351.23	9.18	3,360.41	1,226.40	146.60	1,373.00	1,987.41	2,124.83
	Previous Year	3,170.13	181.10	3,351.23	1,084.67	141.73	1,226.40	2,124.83	2,085.46

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

17 Revenue From Operation **(Rs. in lakhs)**

Particulars	For The Year Ended on 31-03-2021 Rs.
Sale of Products - Domestic	3,369.76
- Export	7.82
Total	3,377.58

18 Other Incomes **(Rs. in lakhs)**

Particulars	For The Year Ended on 31-03-2021 Rs.
Interest Income	0.76
Discount Received	0.25
Balances Written off	2.19
Other Non-Operating Income	2.34
Total	5.54

19 Cost of Material Consumed **(Rs. in lakhs)**

Particulars	For The Year Ended on 31-03-2021 Rs.
Opening Stock	2,096.20
Purchases	2,550.92
Less Closing Stock	2,373.22
Total	2,273.90

20 Changes in Inventories of Finished Goods and Work-in-Progress **(Rs. in lakhs)**

Particulars	For The Year Ended on 31-03-2021 Rs.
Opening Stock (Finished Goods & WIP)	1,693.86
Closing Stock (Finished Goods & WIP)	2,124.74
Total	(430.88)

21 Employee Benefit Expenses **(Rs. in lakhs)**

Particulars	For The Year Ended on 31-03-2021 Rs.
Salaries and Wages	275.10
Contribution to Provident Fund and Other funds & Staff Welfare Exps	16.66
Total	291.76

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

22 Finance Costs

(Rs. in lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.
Interest On Long Term Borrowing	7.61
Other Borrowing Charges	3.18
Total	10.79

23 Other Expenses

(Rs. in lakhs)

Particulars	For The Year Ended on 31-03-2021 Rs.
Administration Charges	14.44
Auditors' Remuneration	2.50
Casual Labour Charges & Wages	82.36
Communication, Courier & Telephone Expenses	10.64
Consumable & Manufacturing Expenses	6.71
Directors Sitting Fees	0.15
Freight , Cartage & Packing	18.01
Licenses & Fees	6.77
Membership Expenses	1.12
Power & Fuel	41.56
Professional & Legal Expenses	7.71
R&D Expenses	4.73
Rent, Rates & Taxes	27.87
Repair & Maintenance Expenses	26.03
Selling & Distribution Expenses	677.26
Software and Hardware Expenses	3.10
Stationery & Printing Expenses	1.83
Travelling & Conveyance Expenses	10.68
Balances Written off	95.57
Total	1,039.04

- 24 In compliance to Accounting Standard 20 on "Earning per share", the calculation of Earnings per Share (Basic and diluted) is as under:

(Rs. in lakhs)

Particulars	Year ended 31.03.2021
A. Profit/Loss attributable to Equity Shareholders	38.99
B. Weighted average No. of Shares	15,713,430
C. Nominal value of equity share	10
D. Basic EPS (Rs.) (A)/(B)	0.25
E. Diluted EPS(Rs.)	0.25

- 25 **Contingent Liabilities:-**
Contingent Liabilities, not provided for:
(As Certified by the Management)

(Rs. in lakhs)

Particulars	Year ended 31.03.2021
Corporate Social Responsibility	67.13
Income Tax Law	1,497.45

- 26 In the opinion of the Management, Current Assets, Loans and Advances shall have the value on realization, in the ordinary course of the business, equal to the amount at which they are stated in the Balance Sheet.
- 27 In compliance of Accounting Standard 17 (AS-17) on "Segment Reporting" as notified under Companies Accounting Standard Rules, 2006, the company is engaged in manufacturing of Fast Moving Consumer Health Products (FMCHP). Considering the nature of business and financial reporting of the company, the company is operating only one segment and hence the segment reporting is not applicable.
- 28 The Company has adopted Accounting Standard 15 on Employee Benefits as per Actuarial Valuation carried out by an independent actuary in the Book of Account of the Company and the Disclosure relating to same which is envisaged under the standard are disclosed as under :

(Rs. in lakhs)

1. Amount of Liability in respect of Gratuity	
<u>Particulars</u>	<u>FY 2020-21</u>
Opening Balance of Obligation	15.82
Add :-	
Current Service Cost	3.26
Past Service Cost	-
Interest Cost	1.03
Banefits Paid	-
Acturial Gain (Loss)	(2.27)
Closing Balance	17.84

(Rs. in lakhs)

2. Amount of obligation recognized in statement of Profit & Loss	
<u>Particulars</u>	<u>FY 2020-21</u>
Current Service Cost	3.26
Past Service Cost	-
Interest Cost	1.03
Expected Return on plan assets	-
Net Acturial Losses (Gain) Recognised in the Year	(2.27)
Expenses Recognised In Statement of Profit & Loss	2.01

29 Previous years' figures are restated or regrouped or rearranged wherever necessary in order to confirm to the current years' grouping and classifications.

30 The outbreak of Coronavirus (COVID-19) pandemic globally and in India is causing significant disturbance and slowdown of economic activity. In many countries, businesses are being forced to cease or limit their operations for long or indefinite period of time. Measures taken to contain the spread of the virus, including travel bans, quarantines, social distancing, and closures of non-essential services have triggered significant disruptions to businesses, resulting in an economic slowdown.

In assessing the recoverability of Company's assets such as Investments, Loans, intangible assets, Goodwill, Trade receivable, Inventories etc. the Company has considered internal and external information upto the date of approval of these financial results. The company has performed sensitivity analysis on the assumptions used basis the internal and external information / indicators of future economic conditions and expects to recover the carrying amount of the assets and management has assessed, as a part of going concern assessment, impact of current event regarding COVID-19 and on entity's operations and forecasted cash flow and management has a positive view regarding the operations of the company.

31 **Additional Information**

a) Reporting under Micro, small & Medium Enterprise Development Act, 2016

The Company has initiated the process of identification of Creditors which falls under category of MSME, the dislouser relating to amount due to MSME are made to the extent information received.

b) Payment to auditor

(Rs. in lakhs)

Payment to Statutory Auditor as	For the year ended on 31st March, 2021 (Amount in Lakhs)
Audit Fees	2.50

DECCAN HEALTH CARE LIMITED

CIN-L72200TG1996PLC024351

247, 2nd floor Dwarakapuri Colony Punjagutta Hyderabad TG 500082 IN

Notes to the Consolidated Financial Statements as at 31st March, 2021

32 Details of Long Term Borrowings (Secured)

Sr. No.	Lender	Nature of facility	Loan Amount	Amount outstanding as at March 31, 2021	Rate of interest (%)	Repayment Terms	Security / Principal terms and conditions
1	Axis Bank	Car Loan	Rs. 69.00 Lakhs	Rs. 27.04 Lakhs	9.15%	Repayable in 60 Monthly Installment of Rs.1,43,735/- Each	Hypothication of BMW car Purchased through Loan
2	HDFC Bank-I	Car Loan	Rs. 52.13 Lakhs	Rs.18.11 Lakhs	10.00%	Repayable in 60 Monthly Installment of Rs.1,10,787/- Each	Hypothication of Benz car Purchased through Loan
3	HDFC Bank-II	Car Loan	Rs. 21.25 Lakhs	Rs.19.40 Lakhs	13.50%	Repayable in 60 Monthly Installment of Rs.48,900/- Each	Hypothication of Mercedes car Purchased through Loan
4	HDFC Bank-III	Car Loan	Rs. 18.14 Lakhs	Rs.13.67 Lakhs	9.50%	Repayable in 60 Monthly Installment of Rs.38,087/- Each	Hypothication of Toyota car Purchased through Loan
5	HDFC Bank-IV	Car Loan	Rs. 4.13 Lakhs	Rs. 3.73 Lakhs	8.50%	Repayable in 60 Monthly Installment of Rs.8434/- Each	Hypothication of Maruti Eco car Purchased through Loan

Related Party Transaction

Names of Related Parties and Description of Relationship

Sr. No.	Nature of Relationship	Name of Related Parties
1	Key Management Personnel	Minto Purshotam Gupta
		Meenakshi M Gupta
		Hitesh Mohanalal Patel
		Yezdi Jal Batliwala
		Narendra Singh
		Savita Bhutani
		Uttam Kumar Singh
		Mohak M Gupta
		Sheena Jain
2	Relatives of Key Person	Mohita M Gupta
3	Subsidiary	Beyoung Store Private Limited
4	Associates /Sister Concern/Enterprise	Nutricircle Limited
		Mintokashi Associates And Investmemts Private Limited
		Mintakashi FMCH Products India (OPC) Private Limited
		Calmour US Private Limited
		DWC Global PVT LTD *
		Speciality Research And Life Sciences **

* DWC Global Private Limited is strike off.

** As per explanation and information provided by the mangagement, Speciality Research and Life Sciences is winded up.

Note: Related parties are identified by the Mangagemnt and relied up on by the Auditor.

(Rs. In Lakhs)

Sr. No.	Nature of Transaction	Associates /Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'20 to March'21	April'20 to March'21
(A)	Volume of Transactions		
1	<u>Remuneration to KMP & Relatives</u>		
	Minto Purshotam Gupta	--	51.19
	Meenakshi M Gupta	--	30.61
	Uttam Kumar Singh	--	7.13
	Mohak M Gupta	--	17.98
	Sheena Jain	--	12.60

Sr. No.	Nature of Transaction	Associates/Sister Concern/Enterprise	Key Management Personnel & Relatives of Such Personnel
		April'20 to March'21	April'20 to March'21
4	Unsecured Loan		
	<u>Hitesh N Patel</u>		
	Loan accepted	--	50.00
	Loan repaid	--	50.00
	<u>Yezdi Jal Batliwala</u>		
	Loan accepted	--	--
	Loan repaid	--	1.50
	<u>Mohita Gupta</u>		
	Loan accepted	--	40.00
	Loan repaid	--	40.00

As per our Report of even date attached

For, Keyur Shah & Co.
Chartered Accountants
F.R.No: 141173W

For & on behalf of Board of Directors

Keyur Shah
Proprietor
M.No. 153774

Minto Gupta
Managing Director
DIN-00843784

Hitesh Patel
Director
DIN-02080625

Place: Ahmedabad
Date : 13th July, 2021

Mohak Gupta
Chief Financial Officer
PAN- ARTPG3989Q

Sheena Jain
Company Secretary
PAN-BCJPJ9626H

FORM NO. AOC.1

Statement containing salient features of the financial statement of Subsidiaries/associate companies/joint ventures (Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

Part "A": Subsidiaries

(Rs. In Lakhs)

1. Name of the subsidiary - **Beyoungstore Private Limited**
2. Reporting period for the subsidiary concerned, if different from the holding company's reporting period -Same as Holding Company
3. Share capital-10,000shares @ 10 each- Rs. 100,000
4. Reserves & surplus- 0
5. Total assets - 1.14
6. Total Liabilities - 1.14
7. Investments - 0
8. Turnover- 0
9. Profit before taxation - 0
10. Provision for taxation -0
11. Profit after taxation-0
12. Proposed Dividend
13. % of shareholding- 100% shareholding

Part "B": Associate and Joint ventures

The Company has no associates and joint venture

NOTICE

Notice is hereby given that the Twenty fifth (25th) Annual General Meeting of the Members of Deccan Health Care Limited will be held on **Thursday, 30th September, 2021**, at **03:00 P.M.** Indian Standard Time through Video Conferencing (VC)/ Other Audio Visual Means (OAVM), to transact the following business:

ORDINARY BUSINESS:

1. To receive, consider and adopt the Audited Financial Statements of the Company for the Financial Year ended 31st March, 2021, together with the Reports of the Board of Directors and the Auditors thereon.
2. To appoint a Director in place of Mr. Hitesh Mohanlal Patel (holding DIN: 02080625) who retires by rotation, in terms of Section 152 (6) of the Companies Act, 2013 and being eligible, offers himself for re-appointment.

SPECIAL BUSINESS:

3. To re-appoint Ms. Ruchi Khattar as an Independent Director and in this regard, pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Ms. Ruchi Khattar (DIN: 01966349), who was appointed as an Independent Director and who holds office of Independent Director up to the conclusion of this Annual General Meeting and being eligible, and in respect of whom the Company has received a notice in writing under Section 160 of the Act from a member proposing his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation and to hold office for a term of 5 (five) consecutive years on the Board of the Company.

4. To re-appoint Ms. Kandlakunta Samhitha as an Independent Director and in this regard, pass the following resolution as an **Ordinary Resolution**:

“RESOLVED THAT pursuant to the provisions of Sections 149 and 152 read with Schedule IV and other applicable provisions, if any, of the Companies Act, 2013 (“the Act”) and the Companies (Appointment and Qualification of Directors) Rules, 2014 and the applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (including any statutory modification(s) or re-enactment(s) thereof, for the time being in force), Ms. Kandlakunta Samhitha (DIN: 08891727), who was appointed as an Independent Director and who holds office of Independent Director up to the conclusion of this Annual General Meeting and being eligible, and in respect of whom the Company has received a notice in writing under Section 160 of the Act from a member

proposing his candidature for the office of Director, be and is hereby re-appointed as an Independent Director of the Company, not liable to retire by rotation and to hold office for a term of 5 (five) consecutive years on the Board of the Company

By order of the Board of Directors
For **DECCAN HEALTH CARE LIMITED**

Sd/-

Sheena Jain

Company Secretary
(ACS: 52795)

Place: Hyderabad

Date: 06.09.2021

NOTES—

1. An Explanatory Statement pursuant to Section 102 of the Companies Act, 2013 ("the Act") relating to the special business to be transacted at the Annual General Meeting (AGM) is annexed hereto.
2. In view of the COVID-19 pandemic, the Ministry of Corporate Affairs ('MCA') issued General Circular Nos.14/2020, 17/2020 and 20/2020 dated 8th April, 2020, 13th April 2020 and 5th May, 2020, respectively and by General Circular No. 02/2021 dated 13th January, 2021, allowed companies whose AGMs were due to be held in the year 2020 or become due in the year 2021, to conduct their AGMs on or before 31.12.2021, in accordance with the requirements provided in paragraphs 3 and 4 of the General Circular No. 20/2020 ("MCA Circulars"). The Securities and Exchange Board of India ('SEBI') also issued Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated 12th May, 2020 the validity of which has been extended till 31st December, 2021 by SEBI, vide its Circular No. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated 15th January, 2021 ("SEBI Circulars"). In compliance with these Circulars, provisions of the Act and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), the 25th AGM of the Company is being conducted through VC/OAVM Facility, which does not require physical presence of members at a common venue. The Members can attend and participate in the AGM through VC/OAVM only. Further, the Company will be availing remote e-voting/ e-voting system for casting vote during AGM from Central Securities Depository Limited (NSDL).
3. In terms of the MCA Circulars since the physical attendance of Members has been dispensed with, there is no requirement of appointment of proxies. Accordingly, the facility of appointment of proxies by Members under Section 105 of the Act will not be available for the 25th AGM. However, in pursuance of Section 112 and Section 113 of the Act, representatives of the Members may be appointed for the purpose of voting through remote e-Voting, for participation in the 25th AGM through VC/OAVM Facility only. Therefore, attendance slip and route map are not annexed to this notice
3. M/s Keyur Shah & Co., Chartered Accountants, having Firm Registration No. 141173W, allotted by The Institute of Chartered Accountants of India (ICAI), Chartered Accountants, the Statutory Auditors of the Company will hold office until the conclusion of the 28th Annual General Meeting of the Company to be held in the year 2024. Pursuant to the notification

dated May 7, 2018, issued by Ministry of Corporate Affairs, the requirement for ratification of appointment of Statutory Auditors by the shareholders at every Annual General Meeting has been done away with. In view of the above, ratification by the members for continuance of their appointment in the ensuing Annual General Meeting is not being sought.

4. Institutional/Corporate members are requested to send at investor@deccanhealthcare.co.in or upload on VC/ OAVM portal, a duly certified copy (PDF/JPEG format) of the Board Resolution authorizing their representative to attend and vote at the Annual General Meeting, pursuant to Section 113 of the Act.
5. As per Rule 20(2) of Companies (Management and Administration) amendment rules, 2015 vide Notification Dated 19th March, 2015, A Company Listed under chapter XB (Companies listed on SME exchange) or chapter XC(Companies listed on institutional trading platform without IPO) of ICDR regulations, 2009 and having its equity Shares listed on a recognized stock exchange, is out of the ambit of E² voting in its General Meeting and DECCAN HEALTH CARE LIMITED is a BSE SME Listed company and E²Voting is not applicable.
6. The Register of Members and Share Transfer Books of the Company will remain closed from Friday, 24nd September, 2021 to Thursday, 30th September, 2021 (both days inclusive) for the purpose of the AGM.
7. The Company's Registrar and Transfer Agent (RTA) for its Share Registry Work (Physical and Electronic) is Bigshare Services Private Limited, having its office at Bigshare Services Pvt. Ltd 306, Right Wing, 3rd Floor, Amrutha Ville, Opp. Yashoda Hospital, Somajiguda, Rajbhavan, Road, Hyderabad - 500082
8. Members can avail of the facility of nomination in respect of shares held by them pursuant to the provisions of Section 72 of the Act. Members holding shares in electronic form may contact their respective Depository Participants for availing this facility.
9. To support the 'Green Initiative', Members who have not yet registered their email addresses are requested to register the same with their Depository Participant for the shares held by them in electronic form.(As Companies 100% shareholding is in Dematerialized form)
10. The Securities and Exchange Board of India (SEBI) has mandated the submission of Permanent Account Number (PAN) by every participant in the Securities Market. Members holding shares in electronic form are therefore, requested to submit the PAN to their Depository Participants with whom they are maintaining their demat accounts.
11. Details under Regulation 36(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations') and in terms of Secretarial Standard-2 in respect of the Directors seeking appointment/ re-appointment and fixation of remuneration at the 25th Annual General Meeting are annexed hereto as Annexure I to this Notice which forms part of the explanatory statement. Requisite declarations have been received from the Directors seeking appointment/re-appointment.

13. Non-Resident Indian members are requested to inform RTA/ respective DP's, immediately of:
 - a) Change in their residential status on return to India for permanent settlement.
 - b) Particulars of their bank account maintained in India with complete name, branch, account type, account number, IFSC Code and address of the bank with pin code number, if not furnished earlier
14. The voting rights of shareholders shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date i.e. Thursday, 23rd day of September, 2020. Members are eligible to cast vote only if they are holding shares as on that date and a person who is not a member as on the cut-off date should treat this notice for information purposes only.
15. A person, whose name is recorded in the register of members or in the register of beneficial owners maintained by the depositories and Company's RTA as on the cut-off date only shall be entitled to avail the facility of voting at the AGM through VC/OAVM.
16. In terms of Section 152 of the Act, Mr. Hitesh Patel, is liable to retire by rotation at this Annual General Meeting and being eligible, offers herself for re-appointment.
17. **ELECTRONIC DISPATCH OF ANNUAL REPORT AND PROCESS FOR REGISTRATION OF EMAIL ID FOR OBTAINING COPY OF ELECTRONIC ANNUAL REPORT:**
 1. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM/EGM has been uploaded on the website of the Company at (www.deccanhealthcare.co.in). The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited at www.bseindia.com respectively. The AGM Notice is also disseminated on the website of CDSL (agency for providing the voting system during the AGM) i.e. www.evotingindia.com.
18. **PROCESS FOR THOSE SHAREHOLDERS WHOSE EMAIL/MOBILE NO. ARE NOT REGISTERED WITH THE COMPANY/DEPOSITORIES.**
 1. For Physical shareholders- please provide necessary details like Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to **Company/RTA email id**.
 2. For Demat shareholders -, Please update your email id & mobile no. with your respective Depository Participant (DP)
 3. For Individual Demat shareholders – Please update your email id & mobile no. with your respective Depository Participant (DP) which is mandatory while e-Voting & joining virtual meetings through Depository.

19. INSTRUCTIONS FOR SHAREHOLDERS ATTENDING THE AGM/EGM THROUGH VC/OAVM ARE AS UNDER:

- (i) In terms of SEBI circular no. SEBI/HO/CFD/CMD/CIR/P/2020/242 dated December 9, 2020 on e-Voting facility at AGM provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Pursuant to abovesaid SEBI Circular, Login method for joining virtual meetings for Individual shareholders holding securities in Demat mode is given below:

Type of shareholders	Login Method
Individual Shareholders holding securities in Demat mode with CDSL	<ol style="list-style-type: none"> 1) Users who have opted for CDSL Easi / Easiest facility, can login through their existing user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are https://web.cdslindia.com/myeasi/home/login or visit www.cdslindia.com and click on Login icon and select New System Myeasi. 2) After successful login the Easi / Easiest user will be able to see the e-Voting option for eligible companies where the evoting is in progress as per the information provided by company. On clicking the evoting option, the user will be able to see e-Voting page of the e-Voting service provider for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. Additionally, there is also links provided to access the system of all e-Voting Service Providers i.e. CDSL/NSDL/KARVY/LINKINTIME, so that the user can visit the e-Voting service providers' website directly. 3) If the user is not registered for Easi/Easiest, option to register is available at https://web.cdslindia.com/myeasi/Registration/EasiRegistration 4) Alternatively, the user can directly access e-Voting page by providing Demat Account Number and PAN No. from a e-Voting link available on www.cdslindia.com home page. The system will authenticate the user by sending OTP on registered Mobile & Email as recorded in the Demat Account. After successful authentication, user will be able to see the e-Voting option where the evoting is in progress and also able to directly access the system of all e-Voting Service Providers.

<p>Individual Shareholders holding securities in demat mode with NSDL</p>	<ol style="list-style-type: none"> 1) If you are already registered for NSDL IDeAS facility, please visit the e-Services website of NSDL. Open web browser by typing the following URL: https://eservices.nsd.com either on a Personal Computer or on a mobile. Once the home page of e-Services is launched, click on the “Beneficial Owner” icon under “Login” which is available under ‘IDeAS’ section. A new screen will open. You will have to enter your User ID and Password. After successful authentication, you will be able to see e-Voting services. Click on “Access to e-Voting” under e-Voting services and you will be able to see e-Voting page. Click on company name or e-Voting service provider name and you will be re-directed to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. 2) If the user is not registered for IDeAS e-Services, option to register is available at https://eservices.nsd.com. Select “Register Online for IDeAS Portal or click at https://eservices.nsd.com/SecureWeb/IdeasDirectReg.jsp 3) Visit the e-Voting website of NSDL. Open web browser by typing the following URL: https://www.evoting.nsd.com/ either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting
<p>Individual Shareholders (holding securities in demat mode) login through their Depository Participants</p>	<p>You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. After Successful login, you will be able to see e-Voting option. Once you click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider name and you will be redirected to e-Voting service provider website for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting.</p>

1. Shareholders are encouraged to join the Meeting through Laptops / IPads for better experience.
2. Further shareholders will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
3. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
4. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance atleast 14 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). The shareholders who do not wish to speak during the AGM but have queries may send their queries in advance 14 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (company email id). These queries will be replied to by the company suitably by email.
5. Those shareholders who have registered themselves as a speaker will only be allowed to express their views/ask questions during the meeting.
6. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility, then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

20. INSTRUCTIONS FOR SHAREHOLDERS FOR E-VOTING DURING THE AGM ARE AS UNDER:-

1. The shareholders should log on to the e-voting website www.evotingindia.com.
2. Click on "Shareholders" module.
3. Now enter your User ID

- a. For CDSL: 16 digits beneficiary ID,
 - b. For NSDL: 8 Character DP ID followed by 8 Digits Client ID,
- OR

Alternatively, if you are registered for CDSL's EASI/EASIEST e-services, you can log-in at <https://www.cdslindia.com> from Login - Myeasi using your login credentials. Once you successfully log-in to CDSL's EASI/EASIEST e-services, click on e-Voting option and proceed directly to cast your vote electronically.

4. Next enter the Image Verification as displayed and Click on Login.

5. If you are holding shares in demat form and had logged on to www.evotingindia.com and voted on an earlier e-voting of any company, then your existing password is to be used.

6. If you are a first time user follow the steps given below:

For Shareholders holding shares in Demat Form and Physical Form	
PAN	Enter your 10 digit alpha-numeric *PAN issued by Income Tax Department (Applicable for both demat shareholders as well as physical shareholders) Shareholders who have not updated their PAN with the Company/Depository Participant are requested to use the sequence number sent by Company/RTA or contact Company/RTA.
Dividend Bank Details OR Date of Birth (DOB)	Enter the Dividend Bank Details or Date of Birth (in dd/mm/yyyy format) as recorded in your demat account or in the company records in order to login. If both the details are not recorded with the depository or company please enter the member id / folio number in the Dividend Bank details field as mentioned in instruction (v).

7. After entering these details appropriately, click on "SUBMIT" tab.

8. Shareholders holding shares in demat form will now reach 'Password Creation' menu wherein they are required to mandatorily enter their login password in the new password field. Kindly note that this password is to be also used by the demat holders for voting for resolutions of any other company on which they are eligible to vote, provided that company opts for e-voting through CDSL platform. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential.

9. For shareholders holding shares in physical form, the details can be used only for e-voting on the resolutions contained in this Notice.

10. Click on the EVSN for the relevant <Company Name> on which you choose to vote.

11. On the voting page, you will see "RESOLUTION DESCRIPTION" and against the same the option "YES/NO" for voting. Select the option YES or NO as desired. The option YES implies that you assent to the Resolution and option NO implies that you dissent to the Resolution.

12. Click on the "RESOLUTIONS FILE LINK" if you wish to view the entire Resolution details.

13. After selecting the resolution you have decided to vote on, click on "SUBMIT". A confirmation box will be displayed. If you wish to confirm your vote, click on "OK", else to change your vote, click on "CANCEL" and accordingly modify your vote.
14. Once you "CONFIRM" your vote on the resolution, you will not be allowed to modify your vote.
15. You can also take a print of the votes cast by clicking on "Click here to print" option on the Voting page.
16. If a demat account holder has forgotten the login password then Enter the User ID and the image verification code and click on Forgot Password & enter the details as prompted by the system.
17. Shareholders can also cast their vote using CDSL's mobile app "m-Voting". The m-Voting app can be downloaded from respective Store. Please follow the instructions as prompted by the mobile app while Remote Voting on your mobile.
18. Only those shareholders, who are present in the EGM/AGM through VC/OAVM facility and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system available during the AGM.
19. If any Votes are cast by the shareholders through the e-voting available during the EGM/AGM and if the same shareholders have not participated in the meeting through VC/OAVM facility , then the votes cast by such shareholders shall be considered invalid as the facility of e-voting during the meeting is available only to the shareholders attending the meeting.

21. Note for Non - Individual Shareholders and Custodians

1. Non-Individual shareholders (i.e. other than Individuals, HUF, NRI etc.) and Custodians are required to log on to www.evotingindia.com and register themselves in the "Corporates" module.
2. A scanned copy of the Registration Form bearing the stamp and sign of the entity should be emailed to helpdesk.evoting@cdslindia.com.
3. After receiving the login details a Compliance User should be created using the admin login and password. The Compliance User would be able to link the account(s) for which they wish to vote on.
4. The list of accounts linked in the login should be mailed to helpdesk.evoting@cdslindia.com and on approval of the accounts they would be able to cast their vote.

5. A scanned copy of the Board Resolution and Power of Attorney (POA) which they have issued in favour of the Custodian, if any, should be uploaded in PDF format in the system for the scrutinizer to verify the same.
6. Alternatively Non Individual shareholders are required to send the relevant Board Resolution/ Authority letter etc. together with attested specimen signature of the duly authorized signatory who are authorized to vote, to the Scrutinizer and to the Company at the email address viz; investor@deccanhealthcare.co.in (designated email address by company), if they have voted from individual tab & not uploaded same in the CDSL e-voting system for the scrutinizer to verify the same.
7. If you have any queries or issues regarding attending AGM & e-Voting from the CDSL e-Voting System, you can write an email to helpdesk.evoting@cdslindia.com or contact at 022- 23058738 and 022-23058542/43.
8. All grievances connected with the facility for voting by electronic means may be addressed to Mr. Rakesh Dalvi, Sr. Manager, (CDSL,) Central Depository Services (India) Limited, A Wing, 25th Floor, Marathon Futurex, Mafatlal Mill Compounds, N M Joshi Marg, Lower Parel (East), Mumbai - 400013 or send an email to helpdesk.evoting@cdslindia.com or call on 022-23058542/43.

22. DECLARATION OF RESULTS:

1. Ms. Monika Bhatia, a Practicing Company Secretary (Membership No. FCS 10397), M/s. M. R. Bhatia & Co, has been appointed as the Scrutinizer to scrutinize the voting process in a fair and transparent manner.
2. The Scrutinizer shall after the conclusion of voting at the AGM, will first count the votes cast at the meeting and thereafter unblock the votes cast through remote e-voting in the presence of at least two witnesses not in the employment of the Company and shall make, not later than 48 hours of the conclusion of the AGM, a consolidated scrutinizer's report of the total votes cast in favour or against, if any, to the Chairman or a person authorized by him in writing, who shall countersign the same and declare the result of the voting forthwith. The results shall be declared not later than forty-eight hours from conclusion of the meeting by posting the same on the website of the Company (www.deccanhealthcare.co.in), website of CDSL (www.evotingindia.com) and by filing with BSE Ltd and It shall also be displayed on the Notice Board at the Registered Office of the Company. Subject to receipt of requisite number of votes, the Resolution shall be deemed to be passed on the date of the Meeting i.e. 30th September, 2021

EXPLANATORY STATEMENT
Pursuant to section 102 of the Companies Act 2013

Item: 3 & 4:-

The Board of Directors of the Company, pursuant to the recommendation of the Governance, Nomination and Remuneration Committee, has proposed to the Members of the Company, the appointments of Ms. Ruchi Khattar(DIN: 01966349) and Ms. Kandlakunta Samhitha (DIN: 08891727), as Independent Directors on the Board of the Company, not liable to retire by rotation, who shall hold office for a term of five consecutive years commencing from 01st October, 2021 to 30th September, 2026.

The Company has received notice in writing from a Member under section 160 of the Companies Act, 2013 ("the Act") proposing the candidature of Ms. Ruchi Khattar and Ms. Kandlakunta Samhitha for the office of Director of the Company. Brief details of Ms. Ruchi Khattar and Ms. Kandlakunta Samhitha are mentioned below:

Ms. Ruchi Khattar is graduate from Lady Sri Ram College, Delhi University. She was associated as a senior member in Max Bupa Health Insurance Company Limited and Max Life Insurance Company Limited. She has 25 years of experience in Accounts, Finance and insurance Compliances etc.

Ms. Kandlakunta Samhitha has done Masters in Business Administrations (MBA) in Finance from University of Dallas, Texas, USA, PG Diploma in Alternative Dispute Resolution NALSAR University of Law and Masters in Law of Financial Services & Capital Markets from NALSAR University of Law, Hyderabad and ICADR, India also she is Certified in Bloomberg Market Concepts. Ms. Samhitha is a Member of the Beta Gamma Sigma, the international honorary society for AACSB accredited business schools and Member of the Sigma Zeta Chapter, Sigma Iota Epsilon National Honorary Management

Place: Hyderabad
Date: 06.09.2021

By order of the Board of Directors
For DECCAN HEALTH CARE LIMITED

Sd/-

Sheena Jain

Company Secretary
(ACS: 52795)

ANNEXURE - I

Details of Director's eligible for appointment/re-appointment pursuant to Regulation 36 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Secretarial Standards-2 (SS-2).

Name of Director	Ruchi Khattar	Kandlakunta Samhitha	Hitesh Mohanlal Patel
Category of Directorship	Independent Director	Independent Director	Non-Executive Director
DIN	01966349	08891727	02080625
Date of Birth	03 rd December, 1971	02 nd April, 1989	14 th June, 1975
Age	49 years	32 years	46 years
Date of Appointment on the Board	24.09.2020	24.09.2020	30.05.2019
Qualification	Ms. Ruchi Khattar is graduate from Lady Sri Ram College, Delhi University.	Ms. Kandlakunta Samhitha has done Masters in Business Administrations (MBA) in Finance from University of Dallas, Texas, USA, PG Diploma in Alternative Dispute Resolution NALSAR University of Law and Masters in Law of Financial Services & Capital Markets from NALSAR University of Law, Hyderabad and ICADR, India also she is Certified in Bloomberg Market Concepts	Higher Secondary examination from Maharastra Board
Experience	Ms. Khattar, aged 49 is associated with the Company as an Additional Director (Independent Director) from 24 th September, 2020. She was associated as a senior member in Max Bupa Health Insurance Company Limited and Max Life Insurance Company Limited. She has 25 years of experience in Accounts, Finance and insurance	Ms. Kandlakunta Samhitha, aged 32 years is associated with the Company as an Additional Director (Independent Director) from 24 th September, 2020. She is Certified in Bloomberg Market Concepts. Ms. Samhitha is a Member of the Beta Gamma Sigma, the international honorary society for AACSB accredited business schools and Member of the Sigma Zeta Chapter, Sigma Iota Epsilon National Honorary Management	Hitesh Patel, aged 46 years is the Promoter and Non - Executive Director of our Company. He has passed his Higher Secondary examination from Maharastra Board. He is the guiding force behind all the strategic decisions. He plays a key role in developing macro investment themes, understanding strengths and weaknesses of specific companies, and indentifying superior management teams. Post

	Compliances etc.		investment, he provides key strategic inputs on strengthening the business model of portfolio companies. He brings a very unique perspective of understanding the value drivers across industries and at the same time has a first-hand understanding of the challenges faced by small to mid-size companies as they scale their businesses
No. of other Directorships in public Ltd Companies	Nil	Nil	1. Nutricircle Limited
Chairman/Member of the Committees of the Board of Directors of the Company.#	Nil	Nil	2
Audit Committees	Nil	Nil	Member, Nutricircle Limited
Stakeholders Relationship Committee	Nil	Nil	Member, Nutricircle Limited
No of Equity Shares held in the Company	0	0	1662014
Number of Board Meetings attended during the year	3/5*	3/5*	5/5
Terms and conditions of appointment/ re-appointment	Independent Director, not liable to retire by rotation	Independent Director, not liable to retire by rotation	Non-executive Director, liable to retire by rotation
Remuneration sought to be paid and the remuneration last drawn	See Note given below	See Note given below	See Note given below
Relationship with Other Directors, Manager and Key Managerial Personnel	No relationship with other Director, Manager and Key Managerial Personnel.	No relationship with other Director, Manager and Key Managerial Personnel.	No relationship with other Director, Manager and Key Managerial Personnel.
Justification for choosing the	The Board is of the view that Ms. Ruchi	The Board is of the view that Ms. Kandlakunta Samhitha's	NA

Independent Director	Khattar's knowledge and experience will be of immense benefit and value to the Company and, therefore, recommends their appointment to the Members	knowledge and experience will be of immense benefit and value to the Company and, therefore, recommends their appointment to the Members	
-----------------------------	--	--	--

#Audit Committee and Stakeholders Relationship Committee have been considered.

*Ms. Ruchi Khattar and Ms. Kandlakunta Samhitha, was appointed as Additional Director (Independent Category) on 24th September, 2021 by the Board of the Company.

Note: The Non-Executive Directors (including Independent Directors) are paid sitting fee for attending meetings of Board of Directors, Independent Directors and various Committee of Directors.

.



CAUTIONARY STATEMENT

This document may contain forward-looking statements, including 'forward-looking statements. Words such as 'will', 'aim', 'expects', 'anticipates', 'intends', 'looks', 'believes', 'vision', or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statement. These forward-looking statements are based upon current expectation and assumptions regarding anticipated developments and other factors affecting the Company. They are not historical facts, not are they guarantees of future performance. Because these forward-looking statement involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statement.

Except as required by any applicable law or regulation, the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Reference in this document to information on websites (and/or social media sites) are included as an aid to their location and such information is not incorporated in, and does not form part of the Annual Report. The brand names shown in this report are trademarks owned by or license.

Except where you are a shareholder, this material is provided for information purposes only and is not, in particular, intended to confer any legal rights on you. This Annual Report and Accounts does not constitute an invitation to invest in Company's shares. Any decision you make in reliance on this information are solely your responsibility. The information is given as of the dates specified, is not updated, and any forward-looking statement are made subject to the reservation specified in the cautionary statement. The Company accepts no responsibility for any information on other websites that may be accessed by hyperlinks.

Designed and produced by DHC Communication.

If you have finished with this document and no longer wish to retain it, please pass it on to other interested readers or dispose of it in your recycled paper waste. Thank you.



Deccan Health Care Limited

247, Dwarakapuri, Punjagutta, Hyderabad. 500082, Telangana

Tel: 91 40 40144508 | www.deccanhealthcare.co.in